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Abstract 
 
A xenobiotic is a foreign chemical substance found in the environment. The 
body removes xenobiotics by xenobiotic metabolism.  Drug metabolizing enzymes (DMEs) 
play central roles in the metabolism, elimination, and detoxification of xenobiotics 
introduced into the body. Orphan nuclear receptors play crucial role in regulation of 
the expression of DMEs. The pig has quickly grown into an important biomedical 
research tool over the past few decades. The pig is an appropriate animal model for 
the investigation of xenobiotic disposition, as the transporters and CYP enzymes are 
very similar to those in humans. The characterization of porcine drug metabolism 
genes and the genes involved in regulating drug metabolism can provide insights into 
human drug metabolic diseases and individual variability of responses toward a drug. 
The tissue- and stage-specific expression of the nuclear receptors in pigs and their 
comparison to humans will be of great interest. Consequently, the goal of the proposal 
is to validate pig as a model of xenobiotic metabolism in order to get a better 
understanding of the pharmacokinetic properties of the xenobiotics. Expression of 
orphan nuclear receptors were screened across various porcine organs (liver, kidney, 
lung, small intestine, spleen, pancreas, heart, brain and skeletal muscle).  Analysis of 
the mRNA expression levels of porcine orphan nuclear receptors in total RNA from 
various porcine organs was also performed by real time reverse transcriptase PCR. 
Expression of all the porcine nuclear receptors studied except (PPARγ) was detected 
in the liver and kidney. Most of the nuclear receptors showed higher expression in the 
liver. The tissue distribution and the expression profiles of the porcine nuclear 
receptors were consistent with those of human. To evaluate the effect of xenobiotic 
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exposure on the expression pattern of the nuclear receptors, expression pattern of 
nuclear receptors were evaluated in three different developmental stages i.e; three 
month old fetus, one month old piglet and one year old adult pig. The expression levels 
of the nuclear receptors in adult tissues were higher than that of one month old piglets 
which in turn were higher than those of a three month old fetal piglet. Porcine orphan 
nuclear receptors liver X receptor alpha (LXRα), liver X receptor beta (LXRβ) and 
constitutive androstane receptor (CAR) were cloned and the sequence analysis 
revealed eight novel transcript variants for LXRα and LXRβ each and five novel 
transcript variants for CAR. The expression profiles and the physiochemical properties 
of the novel identified transcript variants were analyzed. Further, we developed and 
characterized a porcine hepatocyte cell line representative of human primary 
hepatocytes to support drug toxicity and metabolism assessments. Three independent 
hepatocyte cell lines were developed from three different Oncopigs and all of them 
expressed hepatocyte specific and most important drug metabolism and regulation 
genes comparable to those porcine primary hepatocytes. We evaluated the effect of 
selective CYP modulators on three porcine hepatocyte cell lines. All the three 
independent porcine hepatocyte cell lines behaved the same way and the gene 
regulation pattern in hepatocyte cell lines was similar to that of primary hepatocytes 
and human models. These findings indicate that this porcine hepatocyte cell line 
represents a useful and predictive model for high throughput screening of new drugs 
as well as studies on metabolism and hepatotoxicity of chemicals. 
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Chapter 1: General Introduction 
A xenobiotic is a chemical substance found in the environment. Thus, it includes 
pesticides, occupational chemicals, environmental contaminants, clinical drugs, 
deployment-related chemicals and foreign chemicals created by other organisms [1]. 
The body removes xenobiotics by xenobiotic metabolism. Many of the chemical 
reactions involved in the biotransformation of xenobiotics have now been traced to 
particular enzymes. Drug metabolizing enzymes (DMEs) play central roles in the 
metabolism, elimination, and detoxification of xenobiotics introduced into the body [2]. 
DMEs protect the body from the potential harmful effects of the xenobiotics by 
enzymatic modification of the xenobiotics and subsequent disposal. Dozens of 
enzymes responsible for xenobiotic biotransformation and transporters responsible for 
excretion of the xenobiotics have been identified. Analysis of the pig genome has 
revealed high similarity between porcine and human genes, including genes 
associated with xenobiotic metabolism [3]. The characterization of porcine drug 
metabolism genes and the genes involved in regulating xenobiotic metabolism can 
provide insights into human drug metabolic diseases and individual variability of 
responses toward a drug or xenobiotic. 
Major factors that contribute to the failure of a new drug in preclinical and clinical 
studies are toxicity and lack of efficacy. The adverse effects of new drugs are often 
not discovered until preclinical animal safety studies or even clinical trials; 40% of 
drugs fail in preclinical animal studies and 89% of those that reach clinical trials fail 
[4].  There is a critical need for more predictive and reliable in vitro testing methods. A 
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good model can identify issues related to toxicity early in the discovery process 
thereby saving millions of dollars. 
Pig in Biomedical Research 
Pigs are increasingly being used as the major non-rodent animal species of 
choice in biomedical research especially in preclinical toxicological testing of 
pharmaceuticals. The popularity of pig specially minipig in pharmacology, 
pharmacokinetic, and toxicological safety evaluation experiments has increased very 
rapidly over recent years [5]. The pig was first used in research in ancient Greece and 
has quickly grown into an important biomedical research tool over the past few 
decades [3]. The pig is considered to be a good model in biomedical research due to 
its anatomical, physiological and biochemical similarity to humans. Many organs and 
systems including liver, heart, kidneys, brain, reproductive and gastrointestinal system 
show similarities with humans [6]. Similarity in size and physiology to humans allows 
pigs to be used for many experimental approaches not feasible in mice. 
The pig is a true omnivore like human and because of this, the physiology of 
digestion and metabolic processes in the liver are also similar to humans. Similarities 
between pigs and humans in the way they metabolize xenobiotics both in vitro and in 
vivo have been reported by several researchers [7–9]. The Cytochrome P450 enzyme 
system (P450), which is mainly responsible for the biotransformation of xenobiotics  
has been studied in pig and porcine metabolic pathways have been found to be 
relatively similar to human [10]. Pig can be used as a laboratory model for human 
xenobiotic metabolism without the requirement to induce biotransformation enzymes 
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[11]. Analysis of the pig genome has revealed high similarity between porcine and 
human genes, including genes associated with drug metabolism [3]. Metabolism of 
several compounds by pig liver microsomes has been studied [12,13]; a study on 
pharmacokinetics of two model drugs atenolol and 5-aminosalicylate indicates that pig 
may give estimate of pharmacokinetic parameters comparable to those obtained in 
human [14].  
Overview of Xenobiotic Metabolism 
Xenobiotic metabolism, which occurs primarily in the liver and small intestine, 
refers to the enzymatic modification of chemical compounds. Upon conversion to 
hydrophilic compounds, xenobiotics are eliminated from the body through renal or 
biliary routes. Drug metabolizing enzymes (DMEs) play central roles in the 
metabolism, elimination, and detoxification of xenobiotics introduced into the body. 
Drug biotransformation (metabolism) is traditionally classified as phase I and phase II 
metabolism and phase III transport. An overview of xenobiotic metabolism has been 
presented in Figure 1.1. Most of the tissues and organs express diverse and various 
DMEs, including phase I and phase II metabolizing enzymes and phase III 
transporters. These DMEs can be present in abundance at the basal level, or 
expression can be induced after exposure to xenobiotics [15]. 
Phase I metabolism includes oxidation, reduction, hydrolysis, and hydration. 
Enzymes catalyzing these reactions are found in virtually all tissues, especially in the 
hepato-intestinal axis [16]. There are a large number of phase I xenobiotic 
metabolizing enzymes and most prominent is cytochrome P450 (CYP) superfamily. 
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CYP isoforms are found abundantly in the liver, GI tract, lung, and kidney [17]. The 
CYPs detoxify or bio-activate a vast number of xenobiotic chemicals and are involved 
in functionalization reactions that include hydroxylation, N- and O- dealkylation, 
hydroxylation, oxidation and deamination [18]. In humans, five CYP gene families, 
CYP1, CYP2, CYP3, CYP4, and CYP7, are believed to play crucial roles in hepatic 
and extrahepatic metabolism and elimination of xenobiotics and drugs [19]. The 
products of phase I metabolism are generally more polar and more readily excreted 
than the parent compounds and are often substrates for phase II enzymes [16]. 
The pig is an appropriate animal model for the investigation of drug disposition, 
because the transporters and CYP enzymes are very similar to those in humans [20]. 
The CYPs constitute the major enzyme family capable of catalyzing the oxidative 
biotransformation of most drugs and other lipophilic xenobiotics and are of particular 
relevance for clinical pharmacology. Several of these CYP subfamilies have been 
characterized in the pig and minipig [21] and enzymes equivalent to human P450s 
(like CYP1A, CYP2A6, CYP2E1 and CYP3A4) has been identified in pig [11,22]. 
Figure 1.2 shows the relative abundance of the porcine liver P450 enzymes and Table 
1.1 shows their sequence similarity with human equivalent proteins. Moreover, the 
main liver enzyme of drug metabolism (CYP3A) has been reported in pig in 
comparable amounts and activity levels to humans [20]. Minipig cytochrome P450 3A, 
2A and 2C enzymes were found to have similar properties to human analogs [23]. In 
addition, the porcine pregnane X receptor protein which regulates CYP3A has higher 
sequence similarity to that of humans than the mouse gene [24]. That makes the pig 
a better model than the mouse to determine whether a compound is toxic to humans. 
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For these reasons, pigs are considered an ideal model for evaluating the safety of 
pharmaceuticals and biopharmaceuticals [25]. 
Phase II metabolism involves conjugation with endogenous hydrophilic 
compounds to increase polarity and water solubility, thereby increasing excretion in 
the bile and urine, resulting in a detoxification effect. The phase II metabolizing or 
conjugating enzymes, consisting of many superfamily of enzymes including 
sulfotransferases (SULT) and UDP-glucuronosyl transferases (UGT), DT-diaphorase 
or NAD(P)H:quinone oxidoreductase (NQO) or NAD(P)H: menadione reductase 
(NMO), epoxide hydrolases (EPH), glutathione S-transferases (GST)  and N-
acetyltransferases (NAT) [15]. Each superfamily of phase II DMEs consists of families 
and subfamilies of genes encoding the various isoforms with different substrate 
specificity, tissue and developmental expression. The liver microsomal system plays 
the principle role in phase II metabolism and is known for its high metabolic capacity 
[26]. In general, conjugation with phase II DMEs generally increases hydrophilicity, 
and thereby enhances excretion in the bile (Figure 1.1). 
Phase III biotransformation refers to active membrane transporters that function 
to transport xenobiotics across membranes. These transporters are classified as 
primary, secondary and tertiary. Primary transporters derive energy from ATP 
hydrolysis, whereas secondary and tertiary transporters derive energy by an 
exchange of intracellular ions [27]. Phase III transporters play crucial roles in drug 
absorption, distribution, and excretion. They include P-glycoprotein, multidrug 
resistance–associated protein, organic anion transporting polypeptide 2, and ABC 
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transporters. They are expressed in many tissues, including liver, intestine, kidney, 
and brain [15]. 
Regulation of xenobiotic metabolism by nuclear receptors 
Regulating the expression of various drug metabolism enzymes can affect 
metabolism, pharmacokinetics, drug-drug interactions, and their ability to protect the 
human body against exposure to environmental xenobiotics [16]. Several classes of 
xenobiotics induce the transcription of genes encoding biotransformation enzymes 
and transporters. Different nuclear receptors, including orphan nuclear receptors, play 
a crucial role in regulation of the metabolism and clearance of drugs and xenobiotics 
introduced into the body [28]. These receptors are master regulators of the three 
phases of biotransformation [29]. Figure 1.3 represents a schematic diagram how 
nuclear receptors regulate the metabolism of xenobiotics. 
Orphan nuclear receptors comprise a gene superfamily encoding the 
transcription factors that sense endogenous, such as small lipophilic hormones, and 
exogenous, such as drugs, xenobiotics and transfer into cellular responses by 
regulating the expression of their target genes. Regulation of gene expression at the 
transcriptional level by orphan nuclear receptors plays a crucial role in the metabolism 
and clearance of drugs and xenobiotics that are introduced into the body for the 
purpose of protection the body from the environmental insults. 
Important nuclear receptors (NRs) involved in the regulation of phase I, phase II 
metabolizing enzymes and phase III transporters are liver X receptors (LXRα and 
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LXRβ), constitutive androstane receptor (CAR), peroxisome proliferator activated 
receptors (PPARα, PPARβ and PPARγ), retinoid X receptors (RXRα, RXRβ and 
RXRγ), pregnane X receptor (PXR) and farnesoid X receptor (FXR). 
Structural and functional organization of nuclear receptor superfamily 
Regarding the xenobiotic nuclear receptors, the organizational structure of most 
nuclear receptors is quite similar. All NR proteins exhibit a characteristic modular 
structure that consists of five to six domains (designated A to F, from the N-terminal 
to the C-terminal end) on the basis of regions of conserved sequence and function 
(Figure 1.4). The DNA-binding domain (DBD, region C) of the receptor is responsible 
for recognition of the response element in the promoter region of the target gene and 
the ligand binding domain (LBD; region E) of the receptor is where endogenous or 
exogenous ligands bind to the receptor [30]. DBD and LBD domain are the most highly 
conserved domains. These two regions are the most important and can function 
independently. The variable N-terminal A/B domain (AF2) and AF2 (Activation function 
2) region are less conserved and are involved in the binding of the co-regulatory 
proteins and activation of the receptors. The C-terminal F region, which is contiguous 
with the E domain, is not present in all receptors, and its function is poorly understood. 
Liver X Receptors (LXRs) 
Liver X receptors are transcription factors commonly known as cholesterol 
sensors [31]. The two related LXRs; LXRα (NR1H3) and LXRβ (NR1H2) are among 
the emerging significant newer drug targets within the NR family. LXRs are probably 
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best known as nuclear oxysterol receptors and physiological master regulators of lipid 
and cholesterol metabolism and have attracted recent attention because they also 
display anti-inflammatory activities [32]. LXRs generally function as heterodimers with 
retinoid X receptor (RXR) [15]. LXRα and LXRβ bind to a specific DNA sequence, 
called the LXR response element (LXRE), that consists of direct repeats of the 
consensus half-site sequence 5’-AGGTCA-3’ in which the half-sites are spaced by 
four nucleotides (DR4 motif) [15]. Human LXRα (447 amino acids) and LXRβ (460 
amino acids) share 77% sequence similarity in their DBD and LBD. Although LXRs 
were initially discovered as orphan receptors, the search for natural ligands resulted 
in the identification of various oxysterols as strong candidates for endogenous LXR 
agonists. In human, LXRα is predominantly expressed in liver, kidney, spleen and 
intestine, whereas LXRβ is expressed ubiquitously [33]. 
Constitutive Androstane Receptor (CAR, NR1I3) 
The orphan nuclear receptor CAR was identified in 1994 [34] . It was originally 
defined as constitutively activated receptor, because it does not require a ligand for 
its activation. It forms a heterodimer with RXR, which binds to retinoic acid response 
element of the promoter region of its target gene and trans-actives target gene [35]. 
In human, CAR is mainly expressed in liver and less abundantly in intestine [28].  CAR 
is located in the cytoplasm of hepatocytes in the absence of ligands and it is trans-
located into the nucleus after treatment with ligands. 
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Peroxisome Proliferator Activated Receptors (PPARs) 
Currently three members of this nuclear receptor family have been identified as: 
PPARα (NR1C1), PPARβ (NR1C2) and PPARγ (NR1C3) [36]. PPARs have been 
cloned in several species, including humans, rodents, amphibians, teleosts, and 
cyclostome [37]. In human, PPARα is highly expressed in organs involved in fatty acid 
oxidation including the liver, heart, kidney, intestine and adipose tissue. PPARβ is 
mostly expressed in brain, kidney and intestine. PPARγ is expressed in spleen, 
intestine and fat cells. PPARs play a crucial role in regulation of lipoprotein and fatty 
acid metabolism [15]. 
Retinoid X Receptors (RXRs) 
There are three members of the family, RXRα, RXRβ and RXRγ. RXR can form 
heterodimers with other orphan nuclear receptors as a common partner and the 
formation of heterodimer with RXR is a critical step for facilitating the specific binding 
and activation of most of the nuclear receptors [15]. 
Pregnane X Receptor (PXR, NR1I2) 
PXR is now recognized as another key xenosensor of the NR1I nuclear receptor 
subfamily [38]. PXR forms a heterodimer with RXRα and, following ligand activation, 
interacts with a set of core gene promoter elements within xenobiotic-responsive 
enhancer modules that consist typically of DR-3 or ER6 motifs [39]. PXR was first 
cloned from mouse liver four years after discovery of CAR [40]. PXR received its name 
due because the receptor was activated by pregnane (21-carbon) steroids such as 
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pregnenolone 16acarbonitrile (PCN), a synthetic inducer of the CYP3A family of 
steroid hydroxylases [41]. In human, PXR is expressed in liver and intestine at high 
level and in kidney and lung to a lower level [42]. 
Farnesoid X Receptor (FXR, NR1H4) 
Farnesoid X receptor (FXR) is a nuclear receptor that is identified in 1995 and 
encoded by the NR1H4 gene in humans [43]. Chenodeoxycholic acid and other bile 
acids are natural ligands for FXR. FXR also forms heterodimer with RXR and binds to 
FXR response element (FXRE) in the promoter region of its target genes. In human, 
FXR is expressed at high levels in the liver and intestine [15]. 
In vitro Model of Drug metabolism 
Metabolism of a drug or xenobiotics is critical for its pharmacokinetic properties, 
and the liver is the main organ of drug or xenobiotics biotransformation [44,45]. In vitro 
models generate many ADME (absorption, distribution, metabolism and excretion) 
parameters including metabolic stability, drug-drug interaction potential, cell 
proliferation and cytotoxicity [46]. These assays provide a simple and fast way to test 
the potency and toxicity of the new chemical entities. The liver plays a central role in 
drug metabolism and disposition through its phase I and phase II drug metabolism 
enzymes and phase III transporters. Therefore, primary human hepatocytes are 
generally used for drug metabolism and toxicity studies as they provide a complete 
picture of the metabolic fate of xenobiotics in vitro [44,47]. However, their widespread 
use is greatly hindered by the scarcity of suitable human liver samples. Moreover, in 
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vitro phenotypic instability of hepatocytes, the irregular availability of fresh human liver 
for cell harvesting purposes, and the high batch-to-batch functional variability of 
hepatocyte preparations obtained from different human liver donors complicate their 
use in routine testing [48].  Most of the human liver cell lines have poor or fractional 
CYP expression [49]. To date, the lack of a reliable animal model for assessment of 
drug toxicity and metabolism is a major limitation in early high throughput screening 
of xenobiotics.  Immunological and physiological differences between rodents and 
humans represent major constraints for the use of rodent-based models in drug 
screening. Therefore, a large animal model surrogate for human hepatocytes is a very 
important improvement over the current methods for early screening of novel drugs 
and xenobiotics. 
Over the years, the pig has gained increasing importance as a biomedical model 
due to similarities in size, anatomy and physiology with humans [50]. Similarities 
between pigs and humans in the way they metabolize xenobiotics have been reported 
by several researchers [7–9]. CYP enzymes have been extensively studied in pigs 
and enzymes equivalent to human P450 (eg. CYP1A, 2A6, 2E1, 3A4) have been 
identified in pig liver [11,22,51].  The sequence identity between human and porcine 
P450 enzymes is striking, ranging from 72 to 95 % [51]. Biotransformation data 
indicate that the CYP1A, 2A and 3A enzyme systems seem to be functionally very 
similar between pigs and humans [52,53]. Therefore, the pig may be a good animal 
model to study xenobiotic metabolism. 
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Approach: 
Assessing Xenobiotic Metabolism in a Porcine Model 
In order to properly assess xenobiotic metabolism in a porcine model, expression 
of drug metabolism genes across different porcine organs was determined. The 
selected genes are then cloned and sequenced. Splice variants are identified, 
followed by assessment of tissue specific expression profiles of splice variants. In vitro 
drug testing is then performed, followed ultimately by development of the pig model 
(Figure 1.5). 
Thesis outline  
Chapter 1 of this thesis, described early on is a general introduction covering 
overview of xenobiotic metabolism, orphan nuclear receptors and their role in 
regulation of xenobiotic metabolism. Also reviewed is the importance of pig in 
biomedical research. In chapter 2, the expression profiles of porcine orphan nuclear 
receptors across different organs were investigated. The expression pattern of the 
orphan nuclear receptors in different organs in three developmental stages (Three 
month old fetal piglet, one month old piglet and one year old adult pig) were analyzed 
and the following questions were addressed: 1) whether the expression patterns of 
the orphan nuclear receptors was consistent with those of human 2) what is the effect 
of xenobiotic exposure on the expression pattern of the porcine orphan nuclear 
receptors. Chapter 3 describes the identification and characterization of novel 
transcript variants (splice variants) of porcine liver X receptors (LXRα and LXRβ). 
Moreover the role of porcine LXRs in xenobiotic metabolism regulation was analyzed 
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in an in vitro model. Chapter 4 describes the identification and characterization of 
novel splice variants of porcine CAR. The role of CAR in porcine xenobiotic 
metabolism regulation was analyzed in an in vitro model. Chapter 5 describes the 
development of an in vitro porcine model of drug metabolism and toxicity testing. In 
chapter 5, the following questions were addressed: 1) whether the expression values 
of the most important drug metabolism enzymes in porcine primary hepatocytes are 
consistent with that of human. 2) Whether transformed porcine hepatocyte cell line 
can be used as representative of primary hepatocytes in assessment of xenobiotic 
metabolism and toxicity. 
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Figure 1.1. Schematic diagram of overview of xenobiotic metabolism. 
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Figure 1.2. Relative abundance of porcine liver P450 enzymes (adapted from [51]). 
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Figure 1.3. Overview of regulation of xenobiotic metabolism by nuclear receptors (NRs).  
Upon ligand activation, NRs detach from cytoplasmic retention protein (CRP). Then NRs 
translocate to nucleus and induce the transcription of target gene (drug metabolism enzyme 
genes). 
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Figure 1.4. Structural organization of nuclear receptors. 
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Figure 1.5. Overview of research approach. 
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Chapter 2: Tissue specific mRNA expression profiles of porcine orphan 
nuclear receptors that regulate xenobiotic metabolism and transport 
 
Abstract 
Orphan nuclear receptors (NRs) are master regulators for a wide variety of 
physiological processes and metabolism of endogenous compounds and 
exogenous xenobiotics. In the present study, expression of orphan nuclear receptors 
was screened across various porcine organs (liver, kidney, lung, small intestine, 
spleen, pancreas, heart, brain and skeletal muscle).  Analysis of the mRNA 
expression levels of porcine orphan nuclear receptors in total RNA from various 
porcine organs was also performed by real time reverse transcriptase PCR. 
Expression of all the porcine nuclear receptors studied except (PPARγ) was 
detected in the liver and kidney. Most of the nuclear receptors showed higher 
expression in the liver.  To evaluate the effect of xenobiotic exposure on the 
expression pattern of the nuclear receptors, expression pattern of nuclear receptors 
were evaluated in three different developmental stages i.e. 3 month old fetus, 1 
month old piglet and 1 year old adult pig. The expression levels of the nuclear 
receptors in adult tissues were higher than that of 1 month old piglets which in turn 
were higher than those of 3 month old fetal piglet. As the animals get older, they get 
more exposure to the xenobiotics, which induce the expression of the DMEs and 
nuclear receptors. 
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Introduction 
Orphan nuclear receptors (NRs) are transcription factors that play important 
roles in a wide variety of physiological processes, such as cell growth, cell 
differentiation and metabolic homeostasis [1–3]. They also regulate the expression 
of phase I and phase II drug metabolism enzymes (DME) and phase III transporters. 
Regulation of gene expression of DMEs and transporters plays a crucial role in the 
metabolism and clearance of drugs and xenobiotics introduced into the body. Most 
NRs share two functional domains; N-terminal DNA-binding domain (DBD) and C-
terminal ligand binding domain (LBD)[4]. 
The number of NR genes varies considerably from species to species; in 
human, 48 receptors were found, 49 in mouse, 21 in Drosophila, 33 in sea urchin, 
and more than 270 in Caenorhabditis elegans [5–7]). Of the nuclear receptors, 
pregnane X receptor (PXR, NR1I2), constitutive androstane receptor (CAR, NR1I3), 
farnesoid X receptor (FXR, NR1H4), liver X receptor alpha (LXRα, NR1H3), liver X 
receptor beta (LXRβ, NR1H2) and peroxisome proliferator activated receptor alpha 
(PPARα, NR1C1) are primary transcriptional regulators of the genes involved in the 
metabolism and elimination of drugs and xenobiotics [8–11]. Nuclear receptors LXR, 
CAR, FXR, PPAR and PXR regulate gene expression by forming heterodimers with 
the retinoid X receptor [12]. NRs activate or repress target gene transcription through 
interaction with transcriptional co-regulators like co-activators or co-repressors, 
which leads to chromatin modification [13]. 
A considerable degree of cross talk between nuclear receptors and drug 
metabolism enzymes and receptors exists [14]. mRNA expression profiles of nuclear 
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receptors are important for understanding the regulation mechanism of drug 
metabolizing enzymes and transporters. Detailed understanding of transcription 
profiles of nuclear receptors has major implication for screening of new chemicals 
or drugs. The tissue distribution of the important nuclear receptors has been reported 
in human [14]. However, the tissue specific expression pattern of the porcine nuclear 
receptors has been poorly documented. The present study was therefore 
undertaken to study the tissue distribution of mRNA expression of most important 
nuclear receptors linked to xenobiotic metabolism.  The expression patterns of the 
orphan nuclear receptors in three developmental stages (3 month old fetal piglet, 1 
month old piglet and 1 year old adult pig) were also analyzed. 
Materials and Methods 
Animals 
Tissue samples (liver, kidney, lung, small intestine, spleen, pancreas, heart, 
brain and skeletal muscle) were collected from cross pigs (Minnesota Minipig sire X 
Large White Yorkshire dam) maintained in Animal Science Department, UIUC farm. 
Animals were euthanized and the above tissue samples were collected. All tissue 
samples were snap frozen in dry ice and stored at – 80 °C before RNA isolation.  
RNA Isolation  
 Total RNA was isolated from porcine tissues (liver, kidney, lung, small intestine, 
spleen, pancreas, heart, brain and skeletal muscle) using RNeasy Mini Kit (Qiagen) 
as per the manufacturer’s protocol. RNA pellets were dissolved in nuclease-free 
water and stored at -80°C until analysis. Quality of the RNA was determined using 
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NanoDrop spectrophotometer and analyzed by an Agilent 2100 Bioanalyzer to 
determine RNA integrity as well as the presence/absence of gDNA by the Carver 
High-Throughput DNA Sequencing and Genotyping Unit (HTS lab, University of 
Illinois, Urbana, IL, USA). The concentration of the RNA was determined by Qubit® 
RNA HS Assay Kit (Thermo Fisher Scientific, Life Technologies) as per 
manufacturer’s protocol. 
Reverse Transcription PCR (RT-PCR) 
 Tissue distribution of the nuclear receptors was detected by reverse 
transcription PCR. Reverse transcription of RNA was performed from 1 µg total RNA 
in the presence of RNase inhibitor, random hexamer primers (50 ng/µL), 
deoxynucleotides (dNTPs, 10 mM), SuperScript III reverse transcriptase (200 U/µL) 
and reverse transcriptase buffer in a 20 µL final reaction volume using SuperScript 
III First-Strand Synthesis System for RT-PCR kit (Invitrogen,Life Technologies, IN, 
USA). 
 PCR reactions were performed in a 25 µl reaction volume containing 50 ng 
cDNA as the template, 0.5 M of each primer, 2X PCR buffer (including 1.5 mM 
MgCl2), 200 mM dNTPs, and 0.625 units of Taq DNA polymerase. Information on 
PCR primers and thermocycler conditions used are listed in table 2.1.  
Quantitative RT-PCR 
Relative quantification of the genes was analyzed quantitative real time PCR 
(qPCR). qPCR was performed by using Power SYBR green PCR Master Mix (2X) 
(Applied Biosystems) in a Taqman ABI 7900 Real-Time PCR system (Applied 
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Biosystems).  Information on primer used is listed in table 2.2. The thermal cycling 
conditions for real-time PCR were one cycle of 50 °C for 2 min (AmpErase uracil-N-
glycosylase activation) and 95°C for 10 min (AmpliTaq Gold activation), followed by 
40 cycles of 95°C for 15 sec (denaturation) and 60°C for 1 min (annealing and 
extension). The housekeeping gene GAPDH was used as endogenous control to 
normalize for RNA loading or differences in reverse transcription efficiency. For 
preparation of nuclear receptor calibration curves, the total RNA obtained from liver 
was used except for PPARγ, for which total RNA from spleen was used.  
Data Analysis 
The relative expression of each mRNA was calculated by the ΔCt method 
(where ΔCt is the value obtained by subtracting the Ct value of the GAPDH mRNA 
from the Ct value of the target mRNA). The amount of target relative to GAPDH 
mRNA was expressed as 2-(ΔCt). Data are expressed as the ratio of target mRNA to 
GAPDH mRNA. Studies were conducted in triplicate and data are shown as mean 
values. 
Results 
Screening of mRNA expression of porcine orphan nuclear receptors  
The mRNA expression of the porcine orphan nuclear receptors was screened 
across different porcine tissues and the result is presented in table 2.3. Whereas, 
LXRβ transcript was detected in all the organs, expression of LXRα transcript was 
detected in liver, kidney, lung, small intestine and spleen. Expression of CAR was 
detected in liver, kidney, small intestine and spleen. Among the PPAR isoforms, 
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PPARβ was detected in all the tissues screened whereas PPARα was detected in 
liver, kidney, small intestine and heart and PPARγ was detected in small intestine 
and spleen. PXR was detected in liver, kidney, lung and small intestine. FXR was 
detected in liver, kidney and small intestine. Among RXR isoforms, RXRβ was 
detected in all the tissue screened except small intestine; whereas RXRα was 
detected in liver, kidney, lung, spleen, heart and skeletal muscle and RXRγ was 
detected in liver, heart, brain and skeletal muscle. 
Differential mRNA expression of porcine orphan nuclear receptors 
The differential expression of the porcine orphan nuclear receptor mRNAs in 
different tissues was analyzed by quantitative real time PCR. The result of tissue 
specific differential expression profiles of LXRα and LXRβ mRNAs is presented in 
Figure 2.1. Liver and lung showed higher expression of LXRα compared to spleen, 
kidney and small intestine. In case of LXRβ, high expression was detected in liver 
and small intestine. Figure 2.2 shows the relative CAR mRNA expression in various 
porcine tissues. CAR mRNA was expressed at high level at liver and small intestine 
and a relatively lower level at kidney and spleen. The tissue specific differential 
mRNA expression for PPAR isoforms is presented in Figure 2.3. PPARα mRNA was 
expressed at highest in the liver. Highest level of PPARβ and PPARγ mRNAs 
expression was detected in lung and small intestine respectively. PXR and FXR 
mRNAs were expressed at high levels in liver and small intestine, with a very weak 
or no expression in kidney and lung (Figure 2.4 & Figure 2.5). Figure 2.6 shows the 
differential mRNA expression of three RXR isoforms across different porcine tissues. 
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Both RXRα and RXRβ mRNAs were expressed at high levels in the liver. RXRγ 
mRNA was expressed at high levels in skeletal muscle and liver. 
To evaluate the effect of xenobiotic exposure on the expression pattern of 
xenosensors, expression pattern of nuclear receptors were evaluated in three 
different developmental stages i.e. 3-month-old fetus, 1-month-old piglet and 1-year-
old adult pig. The results are depicted in Figure 2.1 to Figure 2.6. It was found that 
the mRNA expressions of all the orphan nuclear receptors increased gradually with 
increase in age of pig.  The mRNA expression levels of the nuclear receptors in fetal 
tissues were very low. The expression levels of the nuclear receptors in adult tissues 
were higher than those of 1 month old piglets which in turn were higher than those 
of 3 month old piglets. As the animals get older, they get more exposure of the 
xenobiotics which may induce the expression of the nuclear receptors. 
Discussion 
Prediction of drug interactions and in vivo clearance of new chemicals and drugs 
are generally done by the ability of the chemicals to induce drug metabolizing 
enzymes and transporters [15]. Nuclear receptors are the master regulators of the 
expression of phase I and phase II drug metabolizing enzymes and phase III 
transporters [16]. Therefore, the tissue distribution and expression profiles of the 
nuclear receptors are crucial to understand the control mechanism of these enzymes 
and transporters. In that context, the present study was designed to investigate the 
tissue-specific mRNA expression profiles of porcine orphan nuclear receptors 
involved in regulation of xenobiotic metabolism. Although rodents are generally used 
as animal models for assessment of drug metabolism and toxicity, they are not 
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reliable predictors of human CYP enzyme inducibility because of divergence of 
amino acid sequences in the ligand binding domain of nuclear receptors leading to 
variation in xenobiotic response [12]. The sequence identity between human and 
porcine P450 enzymes and nuclear receptors is striking, ranging from 72 to 95 % 
[17] making them good large animal model to drug metabolism and toxicity. 
As expected, expression of all the porcine nuclear receptors except (PPARγ) 
was detected in liver and kidney. As the hepato-intestinal axis and kidney play the 
major role in the metabolism and disposition of xenobiotics, the expression of most 
of the nuclear receptors involved in the regulation of xenobiotic metabolism was 
detected. The expression profile of the porcine nuclear receptors was consistent with 
that of human[16,18]. Expression of LXRα and LXRβ was reported in different 
tissues of mouse embryos from 14.5 days postcoitum like liver, lung and small 
intestine [19]. LXRα and LXRβ transcripts were also detected in mouse and human 
placenta [20]. CAR mRNA was expressed at high levels in liver and small intestine 
(Figure 2.2) and PXR mRNA was expressed at high levels in liver and small intestine 
and lower levels at kidney and lung (Figure 2.4). This is consistent with the findings 
of human [14,21–23] and rat [24]. PPARα mRNA was expressed at high level in the 
liver, small intestine and kidney (Figure 2.3). Similar findings were reported in case 
of human PPARα expression [14]. In mice and rat also, PPARα is expressed at high 
levels in the liver, kidney and heart [25,26]. High levels of PPARβ expression was 
found in lung and skeletal muscle (Figure 2.3) which is consistent with those of 
human [14]. The mRNA expression of three isoforms of RXR is consistent with the 
expression pattern in human tissues [14]. 
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To evaluate the effect of xenobiotic exposure on the expression pattern of 
xenosensors, expression pattern of nuclear receptors were evaluated in three 
different developmental stages i.e. 3-month-old fetus, 1-month-old piglet and 1-year-
old adult pig. The expression of the orphan nuclear receptors was found very low or 
basal level in fetal tissues and expression values increased with increase in age of 
pig. This demonstrate that increasing exposure of xenobiotics may induce increased 
expression of nuclear receptors. 
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Figures and Tables 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1. Stage and tissue specific differential expression of porcine LXRα (A) and LXRβ 
(B) 
Real time RT-PCR was performed to analyze the stage and tissue specific expression 
profiles of LXRα and LXRβ. Relative expression values of LXRs were calculated based on 
the assumption that average expression level of housekeeping gene GAPDH is 1.  
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Figure 2.2. Stage and tissue specific differential expression of porcine CAR 
Real time RT-PCR was performed to analyze the stage and tissue specific expression 
profiles of CAR. Relative expression values of CAR were calculated based on the 
assumption that average expression level of housekeeping gene GAPDH is 1.  
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Figure 2.3. Stage and tissue specific differential expression of porcine PPARα (A), PPARβ 
(B) and PPARγ (C) 
Real time RT-PCR was performed to analyze the stage and tissue specific expression 
profiles of PPARs. Relative expression values of PPARs were calculated based on the 
assumption that average expression level of housekeeping gene GAPDH is 1.  
L i
v e
r
S m
a l
l I
n t
e s
t in
e
H e
a r
t
K i
d n
e y
0 .0
0 .1
0 .2
0 .3
0 .4
0 .5
R
el
at
iv
e 
P
P
A
R
α
/G
A
P
D
H
 m
R
N
A
L i
v e
r
S m
a l
l I
n t
e s
t in
e
S p
le
e n
H e
a r
t
B r
a i
n
K i
d n
e y
L u
n g
S .
 M
u s
c l
e
P a
n c
re
a s
0 .0 0
0 .0 5
0 .1 0
0 .1 5
R
el
at
iv
e 
P
P
A
R
β
/G
A
P
D
H
 m
R
N
A
S m
a l
l I
n t
e s
t in
e
S p
le
e n
0 .0
0 .1
0 .2
0 .3
0 .4
0 .5
R
el
at
iv
e 
P
P
A
R
γ /
G
A
P
D
H
 m
R
N
A
(A )
(B )
(C )
3  m o n th -fe ta l
1  m o n th
1  y e a r
3  m o n th -fe ta l
1  m o n th
1  y e a r
3  m o n th -fe ta l
1  m o n th
1  y e a r
40 
 
 
 
 
 
 
 
 
 
Figure 2.4. Stage and tissue specific differential expression of porcine PXR 
Real time RT-PCR was performed to analyze the stage and tissue specific expression 
profiles of PXR. Relative expression values of PXR were calculated based on the 
assumption that average expression level of housekeeping gene GAPDH is 1. 
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Figure 2.5. Stage and tissue specific differential expression of porcine FXR 
Real time RT-PCR was performed to analyze the stage and tissue specific expression 
profiles of FXR. Relative expression values of FXR were calculated based on the 
assumption that average expression level of housekeeping gene GAPDH is 1. 
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Figure 2.6. Stage and tissue specific differential expression of porcine RXRα (A), RXRβ (B) 
and RXRγ (C) 
Real time RT-PCR was performed to analyze the stage and tissue specific expression 
profiles of RXRs. Relative expression values of RXRs were calculated based on the 
assumption that average expression level of housekeeping gene GAPDH is 1.  
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Table 2.1 
Genes  Primers Sequences (5’-3’) Ta1 (°C) 
PXR 
 
Forward CTCCCAGAGGACGGTTTGAA 57 
Reverse AATTCCAGGGTGGTGTAGGC 
FXR 
 
Forward TCAGTCCTTGTCACAGCCAC 57 
Reverse CGCAAACGACACAAAGCTCA 
CAR 
 
Forward AGAAGATGGAGCGCATGTGG 58 
Reverse GGATGCCGTACACAGTCCAT 
LXRα 
 
Forward TAGGAATGGGGTCCAGGCAC 57 
Reverse TCCACTGCAGAGTCAGGAGA 
LXRβ 
 
Forward CAAGGGGACGAAAGCAGCTC 59 
Reverse AGCTGAGCACGTTGTAGTGG 
PPARα 
 
Forward GGGCTTCTTTCGGAGAACCA 61 
Reverse GACGAAAGGCGGGTTATTGC 
PPARβ 
 
Forward TGTGGAAGCAGCTGGTGAAT 58 
Reverse GAAGGGCTTTCGGAGGTCG 
PPARγ 
 
Forward AACATTTCACAAGAGGTGACCA 57 
Reverse GAACCCCGAGGCTTTATCCC 
RXRα 
 
Forward ATGACCCCGTCACCAACATC 61 
Reverse GAGTCCGGGTTGAAGAGGAC 
RXRβ 
 
Forward AGCCATCTTTGACCGGGTG 57 
Reverse CTCAAGCGTGAGGAACACCA 
RXRγ 
 
Forward CGTTCCCCAAACGTGATGCT 60 
Reverse TTCGTTCACTGGCTTTCCAAG 
 
Table 2.1. Primer sequences for reverse transcription PCR 
1Ta denotes annealing temperature 
PXR indicates pregnane X receptor, FXR indicates farnesoid X receptor, CAR indicates 
constitutive androstane receptor, LXR indicates liver X receptor, PPAR indicates 
peroxisome proliferator activated receptor and RXR indicates retinoid X receptor  
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Table 2.2 
Genes  Primers Sequences (5’-3’)  
PXR 
 
Forward GACAACAGTGGGAAAGAGAT 
Reverse CCCTGAAGTAGGAGATGACT 
FXR 
 
Forward CATTCAACCATCACCACGCAGAGA 
Reverse GCACATCCCAGACTTCACAGAGA 
CAR 
 
Forward GAAAGCAGGGTTACAGTGGGAGTA 
Reverse CTTCAGGTGTTGGGATGGTGGTC 
LXRα 
 
Forward TCCAGGTAGAGAGGCTGCAACATA 
Reverse AGTTTCATTAGCATCCGTGGGAAC 
LXRβ 
 
Forward GAGTCTTCCTGAGAGGGGCAGATA 
Reverse CGTGGTAGGCTTGAGGTGTAAGC 
PPARα 
 
Forward AATAACCCGCCTTTCGTCATACAC 
Reverse GACCTCCGCCTCCTTGTTCT 
PPARβ 
 
Forward CCATGCTGTCATGGGTGAAACTCT 
Reverse GTCAACCATGGTCACCTCTTGTGA 
PPARγ 
 
Forward CTTATTGACCCAGAAAGCGATGCC 
Reverse TGTCAACCATGGTCACCTCTTGT 
RXRα 
 
Forward CCTTCTCGCACCGCTCCATA 
Reverse CGTCAGCACCCTGTCAAAGATG 
RXRβ 
 
Forward GGAGCCATCTTTGACCGGGTG 
Reverse CTCAGGCAGCCAAGTTCTGTCTT 
RXRγ 
 
Forward CTTCCCGTTCCCCAAACGTGAT 
Reverse CTTCCAGAAAAGATCCCCAGTCCC 
 
Table 2.2. Primer sequences for real-time PCR 
PXR indicates pregnane X receptor, FXR indicates farnesoid X receptor, CAR indicates 
constitutive androstane receptor, LXR indicates liver X receptor, PPAR indicates 
peroxisome proliferator activated receptor and RXR indicates retinoid X receptor  
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Table 2.3 
 
Table 2. 3. Tissue specific expression of porcine nuclear receptors 
+ denotes detected; - denotes Non-detected; Qualitative reverse transcriptase PCR was 
done to screen the detection of the nuclear receptors in different porcine tissues. 
L indicates liver, K indicates kidney, Lu indicates lung, S.I indicates small intestine, Pan 
indicates pancreas, Hrt indicates heart, B indicates brain, S. Mus indicates skeletal muscle, 
PXR indicates pregnane X receptor, FXR indicates farnesoid X receptor, CAR indicates 
constitutive androstane receptor, LXR indicates liver X receptor, PPAR indicates 
peroxisome proliferator activated receptor and RXR indicates retinoid X receptor 
 
Genes Tissues 
L K Lu S. I Sp Pan Hrt B S. Mus 
LXRα + + + + + - - - - 
LXRβ + + + + + + + + + 
CAR + + - + + - - - - 
PPARα + + - + - - + - - 
PPARβ + + + + + + + + + 
PPARγ - - - + + - - - - 
PXR + + + + - - - - - 
FXR + + - + - - - - - 
RXRα + + + - + - + - + 
RXRβ + + + - + + + + + 
RXRγ + - - - - - + + + 
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Chapter 3: Porcine Liver X receptor: Identification of splice variants and its 
role in regulation of xenobiotic metabolism in an in vitro porcine model 
 
Abstract 
  Liver X receptors LXRα (NR1H3) and LXRβ (NR1H2) are members of the 
nuclear hormone receptor superfamily of ligand-activated transcription factors. Both 
LXRs regulate different metabolic pathways and are involved in the regulation of 
different endogenous metabolites and xenobiotics. In the present study, eight novel 
transcript variants of both LXRα and LXRβ were detected. Molecular modeling 
studies with a synthetic ligand indicate a reduction of the binding affinity of the splice 
variants compared to the wild type proteins. The role of LXRs in xenobiotic 
metabolism in an in vitro porcine model was investigated and it was found that LXR 
modulate expression of a number of cytochrome P450 enzymes to regulate the 
metabolism of xenobiotics. 
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Introduction 
Nuclear receptors are transcription factors that are involved in regulation of 
metabolism of a wide variety of endogenous and exogenous compounds [1]. A total 
of 49 members of this family of transcription factor have been identified in human 
[2]. The transcription factors regulate the expression of the target genes by binding 
to response elements in the promoters of the target genes [3,4]. The binding of 
ligand which varies from metabolic intermediate to xenobiotics triggers either gene 
activation or gene silencing [3]. Nuclear receptors share a common structural motif, 
composed of functionally distinct domains; the N-terminal activation function 1 
domain, the much conserved DNA binding domain (DBD) and the C-terminal ligand-
binding domain (LBD)[4]. Between the DBD and LBD is the hinge domain that 
provides flexibility between these two domains. Activation function 2 is part of LBD 
and is recognized by either coactivators or corepressors [5].  
Liver X receptors LXRα (NR1H3) and LXRβ (NR1H2) are members of the 
nuclear hormone receptor superfamily of ligand-activated transcription factors. LXRs 
form heterodimer with the retinoid X receptor (RXR) to regulate target gene 
expression [6]. Heterodimers of both LXRs with retinoid X receptor (RXR) bind to 
hormone response elements of the DR-4 type, direct repeats of two similar 
hexanucleotide half-sites spaced by four nucleotides [7]. In human, the two LXR 
subtypes are encoded by separate genes and share about 78% amino acid identity 
in the DNA-binding and ligand binding domains [8]. In human, whereas LXRβ is 
broadly expressed, the expression of LXRα is restricted to certain tissues, such as 
liver, small intestine, spleen, kidney, adrenal gland, adipose, and macrophages [7,9–
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11]. The natural ligands of LXRs are thought to be oxidized derivatives of cholesterol 
such as 22(R)-hydroxycholesterol, 24(S), 25-epoxycholesterol and 27-
hydroxycholesterol [9,12]. Both LXRs are key regulators of multiple pathways 
including metabolic, inflammatory and proliferative disease pathways making them 
highly interesting pharmaceutical targets for novel therapies [13,14]. 
Alternative pre-mRNA splicing is responsible for the production of multiple 
mature mRNAs from a single gene, which explains in part how mammalian 
complexity arises from a surprisingly small number of genes [15]. This process is 
essential for the generation of protein diversity at the transcriptional, translational 
and post-translational level [15]. Multiple isoforms have been identified for many 
members of the nuclear hormone receptor family. In several cases, different receptor 
isoforms have been found to have distinct activities and to play distinct biological 
roles [16,17]. Analysis of the pig genome has revealed high similarity between 
porcine and human genes, including genes associated with drug metabolism [18]. 
For these reasons, pigs are considered an ideal model for evaluating the safety of 
pharmaceuticals and biopharmaceuticals [19]. However no information of the 
transcript variants of LXR in pig is available. Role of LXR in xenobiotic metabolism 
in porcine is not well understood. The objective of the present study was to identify 
and characterize transcript variants of porcine LXR and investigate the role of LXR 
in regulation of xenobiotic metabolism in porcine model. In this study we identified 8 
novel LXRα and LXRβ transcript variants each and investigated the properties of the 
transcript variants by molecular modeling studies.  
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Materials and Methods 
Reagents 
All chemicals were purchased from Sigma-Aldrich (USA) unless stated 
otherwise. Cell culture plastics were from Midsci, USA. 
RNA Isolation and cDNA synthesis 
 Total RNA was isolated from porcine tissues using RNeasy Mini Kit (Qiagen) as 
per manufacturer’s protocol. RNA pellets were dissolved in nuclease-free water and 
stored at -80°C until analysis. Quality of the RNA was determined by using Nano 
Drop spectrophotometer. The concentration of the RNA was determined by Qubit® 
RNA HS Assay Kit (Thermo Fisher Scientific, Life Technologies) as per 
manufacturer’s protocol.  
 Reverse transcription of RNA was performed from 1 µg total RNA in the 
presence of RNase inhibitor, random hexamer primers (50 ng/µl), deoxynucleotides 
(dNTPs, 10mM), SuperScript III reverse transcriptase (200 U/µl) and reverse 
transcriptase buffer in a 20 µl final reaction volume using SuperScript III First-Strand 
Synthesis System for RT-PCR kit (Invitrogen, Life Technologies, IN, USA). 
Cloning and sequencing of LXRα and LXRβ genes 
 Based on the exonic regions of the porcine LXRα (NR1H3) and LXRβ (NR1H2) 
genes, cDNAs that together encode the complete ORF of both the genes were 
amplified using the primer sets (Table 3.1). PCR reactions were performed in a 25 
µl reaction volume containing 50 ng cDNA as the template, 0.5 M of each primer, 2X 
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PCR buffer (including 1.5 mM MgCl2), 200 mM dNTPs, and 0.625 units of Taq DNA 
polymerase. PCR reaction conditions were as follows: denaturation at 95 °C for 5 
min, followed by 35 cycles of 95 °C for 30 s, 57°C for LXRα and   60 °C  LXRβ for 
30 s, and 72 °C for 2 min, with a final extension at 72 °C for 20 min. Then, the 5′ and 
3′ untranslated regions of LXRα and LXRβ transcripts from various tissues were 
amplified using total RNA and the FirstChoiceTM RNA ligase-mediated (RLM)-
RACE kit (Ambion, Austin, TX). This procedure used primers supplied with the kit 
and the nested gene-specific primers listed in Table 3.1. These products were 
cloned into pCRTOPO2.1 vector and sequenced. The cDNAs and deduced amino 
acid sequences were analyzed using the Biology Workbench 
(http://workbench.sdsc.edu/).  
Generation of 3-D structure of LXRα and LXRβ and their splice variants 
through homology modeling 
In the absence of crystal structures of porcine LXRα and LXRβ, we opted to 
develop homology models. The deduced amino acid sequences of LXRα and LXRβ 
were analyzed by the Geneious R6 software (www.geneious.com). The query 
sequence was submitted in protein-protein BLAST (Basic Local Alignment Search 
Tool) programme to find out the related protein structure with maximum sequence 
identity, highest score and least E-value to be used as a template 
(http://www.ncbi.nlm.nih.gov/BLAST). The proteins (PDB ID: 1UHL) and (PDB ID: 
1P8) were used as templates for LXRα and LXRβ homology modeling respectively. 
The sequences of the template proteins were retrieved from the protein data bank 
(www.rcsb.org).  
55 
 
LXRα and LXRβ transcript variant sequences were aligned and trimmed by 
Bioedit v7.2.5 software (http://www.mbio.ncsu.edu/bioedit/bioedit.html). The short 
sequences as well as ambiguous alignments were removed. Further, the entropy 
values were predicted. The entropy of each amino acid positions reflects the 
variability of that position along all sequences. Lower entropy indicates high 
predictability of an amino acid at a position whereas high entropy reflects high 
uncertainly.  
All deduced protein sequences of LXRα, LXRβ and their identified transcript 
variants were modeled using MODELLER v9.1 (http://salilab.org/modeller) program 
[20,21]. The sequence-structure matches were established using a variety of fold 
assignment methods, including sequence-sequence, profile sequence, and 
alignments. Each model was evaluated using a multiple scoring algorithm that 
includes length of modeled sequence, identity of structure-sequence alignment, gap 
of alignment, compactness of model, and potential Z-scores. Representative models 
were ranked based on statistical potential value of Discrete Optimizes Potential 
Energy (DOPE) and the best one was selected.  
Evaluation and validation of the3-D structures  
The final modeled structures were validated by Procheck [22] 
(http://services.mbi.ucla.edu/PROCHECK/). Procheck was used to perform full 
geometric analysis as well as stereochemical quality of protein structures. 
Ramachandran plot statistics was used to evaluate the stability of the models.   
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Molecular docking analysis to investigate the interaction of LXRα, LXRβ and 
their splice variants with a synthetic ligand 
T0901317 is a well-known synthetic ligand of both isoform of LXR [23] . To gain 
an understanding of the molecular interactions during ligand binding, molecular 
docking analysis of LXRα, LXRβ and their splice variants with a synthetic ligand 
T0901317 was done. The chemical properties of T0901317 are presented in Table 
3.3. 
Protein and Ligand preparation 
Each modeled proteins were prepared using protein preparation wizard of 
Schrodinger LLC., Portland, USA (http://www.schrodinger.com). This adds 
hydrogen atoms charges, and does energy minimization of the structures using 
Impact Refinement module using OPLS (2005) force field.  The minimization was 
terminated when the energy converged or Root Mean Square Deviation (RMSD) 
reached a maximum cutoff of 0.03Å.  
The ligand T0901317 (CID 447912) (Figure 3.1) was obtained from Pubchem 
database (http://www.pubchem.com). This ligand was built with Chemsketch v12.0 
(ACD Labs, USA; http://www.acdlabs.com), and the 3D structure was further energy 
minimized by LigPrep program (Schrodinger suite LLC., Portland, USA) using the 
OPLS 2005 force field at pH 7.0 and keeping rest of the parameter values as default. 
The pharmacophore model was developed using PHASE 3D-QSAR software [24] 
which utilizes conformational sampling and other scoring parameters to identify the 
common 3D pharmacophore. The pharmacophore model provides a standard set of 
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six pharmacophore features, hydrogen bond acceptor (A), hydrogen bond donor (D), 
hydrophobic group(H), negatively ionizable (N),  positively ionizable (P) and 
aromatic ring (R). Phase analysis predicted 13 sites of hydrogen bond acceptor (A), 
1 site of hydrogen bond donor (D), 5 sites of hydrophobic group (H), and two 
aromatic ring (R) for the ligand T0901317 (Figure 3.1). 
Molecular docking 
The molecular docking was carried out using Glide program [25] of Schrodinger 
suite. Glide is designed to assist in high-throughput screening of potential ligand 
based on binding mode and affinity for a given receptor molecule. Glide provides 
three different level of docking precisions (HTVS, High-Throughput Virtual 
Screening; SP, Standard Precision; XP, Xtra Precision). The entire Glide program 
was run using default mode. Minimization cycle for conjugate gradient and steepest 
descent minimization were used with default value of 0.05 Å for initial step size and 
1.0 Å for maximum step size. In the coincide criteria for minimization, both the energy 
change criteria and gradient criteria were used with default value of 10-7 and 0.001 
kcal/mol respectively. All conformations were considered for docking and in the 
docking process the Glide score was used to select the best conformation for the 
ligand. 
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Effects of T0901317 and GW3965 on transcript expression LXRα, LXRβ, 
SREBP1, FASN and genes involved in phase I, Phase II drug metabolism, 
phase II transport and nuclear receptors 
 T0901317 and GW3965 are well documented potent synthetic agonists of both 
LXR α and LXRβ [23,26]. To gain insight into the role of LXRs in porcine xenobiotic 
metabolism, the effect of the two synthetic ligands on the expressions of the most 
important drug metabolism and regulation genes in porcine primary hepatocytes 
were investigated.   
Cell culture and treatments 
Primary hepatocytes were isolated by using a simplified manual perfusion 
method. Immediately after the animal was euthanized, a single liver lobe was 
resected, washed 2-3 times with ice cold phosphate buffer saline and transported to 
the laboratory in ice cold Krebs Ringer Solution. Then the liver sample was 
cannulated with suitable pipette into visible blood vessels on the cut surface and was 
flushed with 500 ml of buffer A containing 8.3 g/l NaCl, 0.5 g/l KCl, 2.4 g/l HEPES 
and 0.19 g/l EGTA at pH 7.4 and 37°C. This was followed by perfusion of 500 ml 
buffer B containing 8.3 g/l NaCl, 0.5 g/l KCl and 2.4 g/l HEPES. Continuous 
recirculating perfusion was then carried out on the tissue using a pre-warmed 
digestion buffer (Buffer C) solution containing 3.9 g/l NaCl, 0.5 g/l KCl, 2.4 g/l 
HEPES, 0.7 g/l CaCl2 X 2H2O and 0.1 % Collagenase (type IV). Following sufficient 
digestion, the liver capsule was removed and dissolved cells were liberated by gentle 
shaking of the liver specimen in ice cold buffer D containing 9.91 g/l Hanks buffered 
salt without calcium and magnesium, 2.4 g/l HEPES and 2.0 g/l bovine serum 
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albumin. A scalpel was used to cut through the regions which were not well perfused 
to release cells contained within. The resulting cell suspension was filtered through 
a nylon mesh with 100 µm pore size and centrifuged at 50 g for 3 min at 4°C. After, 
we employed a cell incubation step for 10 min with DNase1 containing buffer at 4°C 
during which cell clumps were broken and damaged cells digested. Then the 
resulting suspension was filtered through 70 µm nylon mesh and cells were 
harvested by 50 g for 3 min. This was followed by three washing in ice cold buffer 
D. The resulting cell clumps were finally re-suspended in culture medium (William’s 
E supplemented with 100 mU/ml penicillin, 100 µg/ml streptomycin, 2mM glutamate 
and 10% Fetal bovine serum). Viability of hepatocytes was determined by trypan 
blue dye exclusion test [27]. 
Freshly isolated hepatocytes were cultured in William’s E medium 
supplemented with 100 mU/ml penicillin, 100 µg/ml streptomycin, 2 mM glutamate 
and 10% fetal bovine serum. Prior to experiments, cells were washed twice with PBS 
followed by incubation in medium containing different concentrations of T0901317 
and GW3965. 
Real time PCR 
Total RNA isolation and cDNA synthesis have been done as described 
previously. Relative quantification of the genes involved in phase-I, phase-II drug 
metabolism, phase III transport and  nuclear receptors was performed by using 
Power SYBR green PCR Master Mix (2X) (Applied Biosystems) in Taqman ABI 7900 
Real-Time PCR system (Applied Biosystems). The thermal cycling conditions for 
real-time PCR were one cycle of 50 °C for 2 min (AmpErase uracil-N-glycosylase 
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activation) and 95°C for 10 min (AmpliTaq Gold activation), followed by 40 cycles of 
95°C for 15 sec (denaturation) and 60°C for 1 min (annealing and extension). The 
housekeeping genes GAPDH and ACTB were used as endogenous control to 
normalize for RNA loading or differences in reverse transcription efficiency. The 
information on the primers are presented in table 3.2. The relative expression levels 
were calculated with respect to the normalized expression of the controls by delta 
delta Ct (ΔΔCt) method. 
Results: 
Identification of novel transcript variants of porcine LXRα and LXRβ 
Total eight novel LXRα transcript variants (LXRα-2-9) were detected in different 
porcine tissues (Figure 3.2).  LXRα-1 (wild type) transcript consists of 10 exons 
which code for 447 amino acids. In most of the identified novel transcript variants, 
one or more than one exons were missing leading to truncated amino acids (Figure 
3.2, Figure 3.3 and Table 3.4). LXRα-2 had a shorter 5’ UTR. LXRα-3 had deleted 
exon 6 during splicing. LXRα-4 had missing exons 5, 6 and 7. LXRα-5 deleted a part 
of exon 6. Exons 3 and 4 were missing in LXRα-6, whereas exon 4 was missing in 
LXRα-7. LXRα-8 had deleted exon 9. LXRα-9 used an alternative promoter, so N-
terminal 141 amino acids were deleted. The expression profiles of the different 
variants are indicated in Figure 3.2. LXRα-1 and LXRα-5 were detected in all the 
tissues screened. LXRα-2 and LXRα-3 were detected in liver, kidney, small intestine 
and spleen. LXRα-4 was detected in liver and kidney, LXRα-6 was detected in 
kidney and lung, LXRα-8 was detected in liver and small intestine. LXRα-6 was 
detected in only kidney and LXRα-9 was detected in only lung. The physiochemical 
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properties of the deduced amino acids of the transcript variants of LXRα are 
presented in Table 3.4. 
Similarly, eight novel transcript variants of LXRβ (LXRβ-2-9) were detected 
(Figure 3.4). LXRβ-1 (wild type) consists of 10 exons which codes for 458 amino 
acids. The identified splice variants code for truncated amino acids except LXRβ-3 
which codes for 468 amino acids (Table 3.5). LXRβ-2 had a shorter 3’ UTR. LXRβ-
3 had a 30 nucleotide insert between exon 4 and 5. LXRβ-4 had deleted exon 4, 
whereas LXRβ-5 had deleted exon 5.  LXRβ-6 used an alternative promoter, so N-
terminal 79 amino acids were missing.  LXRβ-7 had deleted part of exon 10 and 
LXRβ-8 had deleted exon 7, 8, 9 and part of exon 10. LXRB9 had missing 223 amino 
acids from N-terminal. The expression of the different variants are indicated in the 
Figure 3.4. The wild type was detected in all the tissues screened.  LXRβ-2 was 
detected in liver, small intestine, pancreas and brain.  LXRβ-3 and LXRβ-9 were 
detected only in kidney. LXRβ-4 was detected in liver, kidney, heart and brain. LXRβ-
5 was detected in kidney, lung, spleen and brain. LXRβ-6 was detected only in liver. 
LXRβ-7 was detected in liver and pancreas. LXRβ-8 was detected in liver, small 
intestine and brain. The physiochemical properties of the deduced amino acids of 
the transcript variants of LXRβ are presented in Table 3.5. 
Reduced binding affinity of the novel transcript variants of porcine LXRα and 
LXRβ towards ligand T0901317 compared to the wild type proteins 
In the absence of crystal structures for porcine LXRα and LXRβ, we opted to 
develop homology models (Figure 3.5 & Figure 3.6). The molecular interactions of 
LXRα transcript variants with synthetic ligand T0901317 are presented in Figure 3.7 
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and Figure 3.8. The binding affinity, interacting amino acids in LBD, and hydrogen 
bond distance of different LXRα transcript variants with T0901317 is presented in 
Table 3.5. The results showed that the wild type protein LXRα-1 has the highest 
binding affinity (Glide score of -5.11 Kcal/mol). The other transcript variants had 
reduced binding affinity for the synthetic ligand. LXRα-8 showed lowest binding 
affinity (Glide score of -2.14 Kcal/mol). The three dimensional conformations of the 
novel splice variant proteins have been changed due to splicing. The disturbed 3-D 
conformation may be the reason behind reduced binding affinity towards its ligand. 
Similarly, the docked conformations of LXRβ transcript variants with synthetic 
ligand is presented in Figure 3.10 and Figure 3.11. The binding affinity, interacting 
amino acids in LBD, and hydrogen bond distance of different LXRβ transcript 
variants with T0901317 is presented in Table 3.7. The results showed that the wild 
type protein LXRβ-1 had highest affinity   energy -5.50 kcal/mol towards T0901317. 
The other splice variants had reduced affinity for the synthetic ligand. The splice 
variants LXRβ-3, LXRβ-7, LXRβ-8 and LXRβ-9 showed low binding affinity.   
T0901317 and GW3965 modulates the expression of LXRs and their 
downstream target genes in porcine primary hepatocytes 
T0901317 [28] and GW3965 [26] are effective, synthetic, non-steroidal agonists 
of LXRs and are the most commonly used agonists for investigating the physiological 
role of LXRs. Both the ligands upregulated LXRs transcripts in porcine primary 
hepatocytes (Figure 3.12).  
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SREBP1 and FASN are two well documented downstream target gene of LXRs [29]. 
Upon T0901317 and GW3965 treatment, expressions of LXR target genes SREBP-
1 and FASN were up-regulated on a dose dependent manner in primary porcine 
hepatocytes (Figure 3.13).  
Liver X receptor agonists modulate the expression of genes involved in 
xenobiotic metabolism in porcine primary hepatocytes 
To gain understanding how LXRs are involved in the xenobiotic metabolism 
pathways, we induced LXRs by addition of synthetic ligands and studied the 
expressions of the most important genes involved in xenobiotic metabolism and its 
regulation. We treated primary hepatocytes with T0901317 and GW3965 to activate 
LXRs and studied the expression of phase-I, phase-II drug metabolism genes and 
phase-III transporters to understand the involvement of LXRs in xenobiotic 
metabolism pathways. Treatment of both T0901317 and GW3965 caused a 
significant increase of CYP2B22, CYP2C42, CYP3A and CYP7A1; all the other 
CYPs remain unchanged (Figure 3.14). T0901317 caused higher fold changes than 
GW3965. Phase II drug metabolism genes remained unchanged. All the three 
nuclear receptors studied (ABCB1, ABCC2, ABCG1 and ABCG2) were upregulated 
(Figure 3.14).  From the results of the study, it can be concluded that activated LXRs 
induce the expression of CYP2B22, CYP2C42, CYP3A and CYP7A1 and the 
transporters (ABCB1, ABCC2, ABCG1 and ABCG2). 
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Discussion 
Nuclear receptors are master regulators of a wide variety of metabolism 
including endogenous metabolites and exogenous xenobiotics that integrate the 
homeostatic control of almost all biological processes [13]. Nuclear receptors 
regulate transcription through the recruitment of coactivator proteins to the ligand 
binding domain (LBD) [30]. The liver X receptors, LXR alpha (NR1H3) and LXR beta 
(NR1H2) are transcription factors belonging to the nuclear receptor superfamily that 
function as intracellular receptors for  cholesterol metabolites, different endogenous 
metabolites and xenobiotics [7,12,31]. The LXRs form heterodimers with the retinoid 
X receptor to regulate the important aspects of homeostasis through their target 
genes [32–34]. In the present study, eight novel splice variants of both LXRα and 
LXRβ were identified. The splice variants had truncated amino acids in the protein 
sequences (Table 3.4 and Table 3.5). In human, three novel LXRα isoforms were 
reported by Chen et al., 2005 [35] and another two novel LXR α isoforms were 
reported by Endo-Umeda et al., 2012 [36]. LXRα2 lacks the N-terminal 45 amino 
acids of LXRα1 and LXRα3 lacks 50 amino acids in the ligand binding domain [35]. 
LXRα3 mRNA is generated by removal of exon 6 through alternative splicing [35]. 
No information of LXRβ isoforms in human is available. 
Synthetic nonsterol LXR agonists have been identified, including T0901317 [26], 
a lipophilic tertiary sulfonamide that contains an acidic bis-trifluoromethyl carbinal 
group. Structural and biochemical studies reveal that the coactivator contains a short 
alpha helical sequence known as NR box that binds the nuclear receptor LBD. The 
NR box is capped by a charge clamp on the surfaceof the LBD formed by a lysine 
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on helix 3 and a glutamic acid on the C-terminal AF2 helix [37]. The molecular 
modeling of porcine LXRα and LXRβ with synthetic ligand T0901317 shows that Trp-
443 and Trp-457 play a significant role in ligand binding respectively (Figure 3.10). 
Crystal structure of human LXRβ also reveals that the residue is Trp-457 and His-
435 is important for ligand activation [39]. The X-ray three dimentional structure of 
the human LXRβ showed that the ligand binding pocket of LXRβ is a large 
hydrophobic cavity that is surrounded by H3, H5, H6, H7, H11 and H12 [3]. In human 
homology model of LXRα indicated that  Trp-443 plays a role in the activation of the 
receptor [38]. Agonists bind to LXRα in an orientation that generates a hydrogen 
bond between the ligand and Trp443 [38]. Similar findings are observed in the 
molecular modeling studies with porcine LXRα and T0901317 (Figure 3.8). 
To gain understanding how LXRs are involved in the xenobiotic metabolism 
pathways, we induced LXRs by addition of synthetic ligands and studied the 
expressions of the most important genes involved in xenobiotic metabolism and its 
regulation. Treatment of both T0901317 and GW3965 caused a significant increase 
of CYP2B22, CYP2C42, CYP3A and CYP7A1 (Figure 3.14). In case of human, 
regulation of CYP3A , CYP 2B 6 and CYP7A1 by LXR has been reported [40].  
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Figures and Tables 
 
 
 
 
 
 
Figure 3.1. Pharmacophore sites of T0901317 
HBA denotes hydrogen bond acceptor, HBD denotes hydrogen bond donor, H denotes 
hydrophobic group and AR denotes aromatic ring.  
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Figure 3.2. Identified transcript variants of LXRα 
The tissue distribution of the splice variants are indicated in the right side.  
Li, Liver; K, Kidney; Lu, Lung; S.I, Small Intestine, Sp: Spleen 
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Figure 3.3. Multiple sequence alignment of LXRα transcript variants 
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Figure 3.4.  Identified transcript variants of LXRβ 
The tissue distribution of the splice variants are indicated in the right side.  
Li, Liver; K, Kidney; Lu, Lung; SI, Small Intestine; Sp, Spleen; Pan, Pancreas; Hrt, Heart; 
Br, Brain 
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Figure 3.5. Multiple sequence alignment of LXRβ transcript variants 
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Figure 3.6. Homology modeled LXRα transcript variants 
A, LXRα-1; B, LXRα-2; C, LXRα-3; D, LXRα-4; E, LXRα-5; F, LXRα-6; G, LXRα-7; H, LXRα-
8; I, LXRα-9 
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Figure 3.7. Homology modeled LXRβ transcript variants 
A, LXRβ-1; B, LXRβ-2; C, LXRβ-3; D, LXRβ-4; E, LXRβ-5; F, LXRβ-6; G, LXRβ-7; H, LXRβ-
8; I, LXRβ-9 
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Figure 3.8. Molecular modeling interactions of LXRα transcript variants with its synthetic 
ligand T0901317 
A. Wild type (LXRα-1); B, LXRα-7; C, LXRα-8; D, LXRα-9 
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Figure 3.9. Molecular modeling interactions of LXRα transcript variants with its synthetic 
ligand T0901317 
A, LXRα-2B; B, LXRα-3; C, LXRα-5; D, LXRα-6 
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Figure 3.10. Molecular modeling interactions of LXRα transcript variants with its synthetic 
ligand T0901317 
A, Wild type (LXRβ-1); B, LXRβ-9; C, LXRβ-7; D, LXRβ-8 
 
76 
 
 
Figure 3.11. Molecular modeling interactions of LXRα transcript variants with its synthetic 
ligand T0901317 
A, LXRβ-2; B, LXRβ-3; C, LXRβ-4; D, LXRβ-5 
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Figure 3.12. Effect of T0901317 and GW3965 on expression of LXRα and LXRβ transcripts 
in primary porcine hepatocytes 
Real time RT-PCR was performed to analyze the effect of LXR ligands T0901317 and 
GW3965 (10 µM) on expression of LXRα and LXRβ transcripts in primary hepatocytes. The 
values and error bars represent average and standard deviations of three independent set 
of experiments. One-way analysis of variance (ANOVA) followed by Dunnett post-test was 
performed to find out significant difference among control and treatments. *** denotes 
p≤0.001; **** denotes p≤0.0001. 
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Figure 3.13. Effect of T0901317 and GW3965 on expression of LXR target genes SREBP1 
and FASN transcripts 
Real time RT-PCR was performed to analyze the effect of LXR ligands T0901317 and 
GW3965 on expression of two downstream target genes of LXR, SREBP1 and FASN. The 
values and error bars represent average and standard deviations of three independent set 
of experiments. 
 
79 
 
 
Figure 3.14. Effect of T0901317 and GW3965 on expression of phase-I, phase-II and 
Phase-II DME transcripts 
Real time RT-PCR was performed to analyze the effect of LXR ligands T0901317 and 
GW3965 (10 µM) on expression of the most important genes involved in regulation of drug 
metabolism. The values and error bars represent average and standard deviations of three 
independent set of experiments. One-way analysis of variance (ANOVA) followed by 
Dunnett post-test was performed to find out significant difference among control and 
treatments. * denotes p≤0.05; ** denotes p≤0.01; *** denotes p≤0.001; **** denotes 
p≤0.0001. 
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Table 3.1 
 
 
 
 
 
 
 
 
 
Table 3.1. Primer sequences for LXRs cloning and RACE 
 
 
 
 
 
 
 
 
 
 
 
 
Cloning Primers 
LXRα Forward GCTCGGACAGTCCCTTGGTA 
LXRα Reverse AGTCACGCCTCAGCCATCTA 
LXRβ Forward CCACTGGTGTTCGGAGAGG 
LXRβ Reverse CCCAGATCTCGGACAGCAAA 
CAR Forward TGAAGGCCACAGAGGTAGAAGTTCCTTG 
CAR Reverse AGCAGCGGCATCATGGTGGACAGTCC 
RACE Primers 
3’RACE-outer  Supplied with kit 
LXRα- 3’-outer GAGTTTGCCCTGCTCATTGC 
LXRβ- 3’-outer TGCTTTCCTACACCCGCATC  
CAR 3' OUTER TAAGACACTTCGGCGACTGC 
3’RACE-inner  Supplied with kit 
LXRα -3’-inner CTGCATGCCTACGTCTCCA 
LXRβ-3’-inner CACTCCGAGCAGGTCTTCG 
CAR 3' INNER TCTCCGGGACAGGTTTCTCT 
5’RACE-outer  Supplied with kit 
LXRα -5’-outer TGCTTGCATCTTGTGCATCTGA 
LXRβ -5’-outer TCCATCGGATGAAGACGACAGA 
CAR 5' OUTER  CTTGCAGCCCTCACAAGTCAAG 
5’RACE-inner Supplied with kit 
LXRα -5’-inner TCTCTTCCTGGAGCCCTGGACATT 
LXRβ -5’-inner TTGTGGGGGTCTCCTACTTTTGTTGC 
CAR5' INNER  CCGCACACAGCACAGTTCCTTG 
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Table 3.2 
Genes Primers Sequences (5’-3’)  
GAPDH 
 
Forward GGCAAATTCCACGGCACAGTCA 
Reverse CTGGCTCCTGGAAGATGGTGAT 
 ACTB 
 
Forward GCAAATGCTTCTAGGCGGACTGT 
Reverse CCAAATAAAGCCATGCCAATCTCA 
Porcine 
Albumin 
Forward TGGTGACTTGGCTGACTGCTG 
Reverse TGTCGGGGTTATCATTTTTGTGTTG 
HNF4A 
 
Forward AGTCCCAGAGTGGTAGTGGAAAG 
Reverse CAGATGGTGAAGGGTGGCATTG 
G6PC 
 
Forward ATTGAAAGACGATGACTGTGCCAA 
Reverse CAAAGGAGGAAGGAGTTCTGAGC 
CYP1A1 
 
Forward AAGAGGCAGAGGTGAAGTGGTGAA 
Reverse GAGAAGAAGGAAGGCAGTGAAGTGATAG 
CYP1A2 
 
Forward ACACCTTCTCCATTGCCTCAGACC 
Reverse GCACTCAGCCTCCTTGCTCAC 
CYP2A19 
 
Forward CCGAAGAGTCACCAAGGATACCAAG 
Reverse ACAGAGCCCAGCATAGGGAACA 
CYP2B22 
 
Forward CAGATGAGTAAACAGAGCCCGAGAA 
Reverse CGAGAGCCAAGGAGACAGCA 
CYP2C33 
 
Forward TGGAAGAAAAATCACAAGAGGAGAAGG 
Reverse TTGGAAAGAGACGCAGGGATGT 
CYP2C42 
 
Forward TACAGAGACAACAAGCACCACCA 
Reverse CTGCCAATCACACGGTCAATC 
CYP2C49 
 
Forward CTTGTGGAGGAGTTGAGAAAAACC 
Reverse TTGTGGAAAATGATGGAGCAGA 
CYP2E1 
 
Forward ACACCCTGCTGATGGAAATGGA 
Reverse GTGGTCTCTGTCCCCGCAAA 
CYP3A 
 
Forward TACCTGCCCTTTGGGACTGGAC 
Reverse AGTTCTGCAGGACTCTGACGA 
CYP7A1 
 
Forward TTCTGCTACCGAGTGATGTTTGAGG 
Reverse AGGTTGTTTAGGATGAGTGCTTTCTGTG 
SULT1A3 
 
Forward GACCACAGCATCTCAGCCTTCAT 
Reverse CTGCCATCTTCTCAGCATAGTCG 
SULT2A1 
 
Forward AAATGCTGCAAGAGGTGAGGGAGG 
Reverse ATCCCCCTTGGAGAGAATCAGGCA 
SULT1E1 
 
Forward GAGAAAGGGGATTGCAGGAGACTG 
Reverse GTAGACCCCTTCATTTGCTGCTCA 
GSTO1 
 
Forward GAGATTCTGTCCTTTCGCCCAGAG 
Reverse GATGACTTGATGCCGGATTCCCTT 
GSTK1 
 
Forward GGTACACCATCCACCGTTAGTCTC 
Reverse CACACAAACACCAGCAAAGACACA 
ABCB1 
 
Forward TGGCAGTGGGACAGGTTAGTTC 
Reverse CACGGTGCTTGAGCTGTCAATC 
ABCB6 
 
Forward TGTTGTCCCAAGGTGGTGTGTATG 
Reverse GCTGAAATGGATTTCCCTCCAGGT 
ABCC2 
 
Forward GTGGCTGTTGAGCGAATAAATGAATAC 
Reverse TGCTGGGCCAACCGTCTG 
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Table 3.2 (cont.) 
Gene 
Name 
Primers Sequences (5’-3’)  
ABCC3 
 
Forward TGATGCAGACGCTGATCTTACACC 
Reverse ACTCACGTTTGACGGAATTGGTGA 
ABCG2 
 
Forward GATCTTTTCGGGGCTGTTCCTCA 
Reverse TGAGTCCCGGGCAGAAGTTTTGT 
PXR 
 
Forward GACAACAGTGGGAAAGAGAT 
Reverse CCCTGAAGTAGGAGATGACT 
FXR 
 
Forward CATTCAACCATCACCACGCAGAGA 
Reverse GCACATCCCAGACTTCACAGAGA 
CAR 
 
Forward GAAAGCAGGGTTACAGTGGGAGTA 
Reverse CTTCAGGTGTTGGGATGGTGGTC 
LXRA 
 
Forward TCCAGGTAGAGAGGCTGCAACATA 
Reverse AGTTTCATTAGCATCCGTGGGAAC 
LXRB 
 
Forward GAGTCTTCCTGAGAGGGGCAGATA 
Reverse CGTGGTAGGCTTGAGGTGTAAGC 
PPARA 
 
Forward AATAACCCGCCTTTCGTCATACAC 
Reverse GACCTCCGCCTCCTTGTTCT 
PPARG 
 
Forward CCATGCTGTCATGGGTGAAACTCT 
Reverse GTCAACCATGGTCACCTCTTGTGA 
RXRA 
 
Forward CCTTCTCGCACCGCTCCATA 
Reverse CGTCAGCACCCTGTCAAAGATG 
RXRG 
 
Forward CTTCCCGTTCCCCAAACGTGAT 
Reverse CTTCCAGAAAAGATCCCCAGTCCC 
SREBP-1 
 
Forward ATCGACTACATCCGCTTCCTTCAG 
Reverse TCCTTCAGAGACTTGCTTTTGTGG 
FASN 
 
Forward AGCTACTGGAGGGGCTATTGCAT 
Reverse CTGCTTACACTCTTCCCAGGACAA 
 
Table 3.2. Primer sequences for real-time PCR 
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Table 3.3 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.3: The Chemical properties of T0901317 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S.No Name Unit 
1 Molecular Weight 481.332709 g/mol 
2 Molecular Formula C17H12F9NO3S 
3 XLogP3 4.9 
4 Hydrogen Bond Donor 
Count 
1 
5 Hydrogen Bond 
Acceptor Count 
13 
6 Rotatable Bond Count 5 
7 Exact Mass 481.039418 g/mol 
8 Monoisotopic Mass 481.039418 g/mol 
9 Heavy Atom Count 31 
10 Potential Energy OPLS-
2005 
123.298 
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Table 3.4 
 
 
 
 
 
 
 
Table 3.4. Properties of deduced LXRα transcript variant proteins 
 
 
 
 
 
 
 
 
 
 
 
 
LXRα 
transcript 
variants 
Amino 
acid 
length 
MW 
(kDa) 
Isoelectric 
Point 
Ramachandran 
plot (allowed 
regions %) 
LXRα-1 447 50.328 6.73 89% 
LXRα-2 447 50.328 6.73 89% 
LXRα-3 387 43.497 7.01 87% 
LXRα-4 284 31.846 6.66 88% 
LXRα-5 417 46.852 6.67 87% 
LXRα-6 295 33.847 5.88 87% 
LXRα-7 358 40.142 4.74 87% 
LXRα-8 400 44.142 5.23 89% 
LXRα-9 306 35.545 7.22 87% 
85 
 
Table 3.5 
 
 
 
 
 
Table 3.5. Properties of deduced LXRβ transcript variant proteins 
 
 
 
 
 
 
 
 
 
 
 
 
LXRβ 
transcript 
variants 
AA 
length 
MW 
(kDa) 
Isoelectric 
Point 
Ramachandran 
plot (allowed 
regions %) 
LXRβ-1 458 50.283 8.00 86 
LXRβ-2 458 50.283 8.00 86 
LXRβ-3 468 51.464 7.83 87 
LXRβ-4 414 46.194 8.78 88 
LXRβ-5 361 39.433 5.47 87 
LXRβ-6 379 42.467 8.66 89 
LXRβ-7 433 47.329 7.58 88 
LXRβ-8 285 29.745 8.44 88 
LXRβ-9 235 27.242 7.06 87 
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Table 3.6 
 
Table 3.6. Binding affinity and molecular interactions of LXRα transcript variants with its 
ligand T0901317 
 
 
 
 
 
 
 
 
 
 
 
 
 
LXRα 
transcript 
variants 
GScore 
(Kcal/mol) 
Interacting 
AAs 
Interaction 
Atoms 
HB-
distance 
(Å) 
LXRα-1 -5.11 
TRP433 
GLN210 
HIS421 
(H…N) 
(H…N) 
(H…O) 
1.94 
2.81 
2.99 
LXRα-2 -5.11 
TRP433 
GLN210 
HIS421 
(H…N) 
(H…N) 
(H…O) 
1.94 
2.81 
2.99 
LXRα-3 -4.01 TRP383 LYS216 
(H…O) 
(N…O) 
2.16 
2.72 
LXRα-4 -4.03 TRP280 (N…O) 2.83 
LXRα-5 -3.20 MET268 ALA264 
(N…O) 
(O…H) 
2.72 
2.86 
LXRα-6  -3.50 GLU289 (O…H) 2.32 
LXRα-7  -3.20 THR169 (O…H) 2.84 
LXRα-8  -2.14 THR370 (O…H) 3.58 
LXRα-9 -3.09 HIS280 (N…O) 2.78  
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Table 3.7 
 
 
 
 
 
 
 
Table 3.7. Binding affinity and molecular interactions of LXRβ transcript variants with its 
ligand T0901317 
 
 
 
 
 
 
 
 
 
 
LXRβ 
transcript 
variants 
GScore 
(Kcal/mol) 
Interacting 
AAs 
Interaction 
 Atoms 
HB-
distance 
(Å) 
LXRβ-1 -5.50 TRP454  (N…O) 1.74 
LXRβ-2 -5.50 TRP454  (N…O) 1.74 
LXRβ-3 -2.31 TRP231  (N…O) 2.22 
LXRβ-4 -4.03 GLU427 (N…O) 2.83 
LXRβ-5 -3.09 HIS335 (O…H) 1.17 
LXRβ-6 -3.14 GLU408  (O…N) 2.61 
LXRβ-7 -2.20 HIS432 (O…H) 2.73 
LXRβ-8 -2.15 GLU281 (H…O) 1.20 
LXRβ-9 -2.05 SER210 TRP231 
(O…H) 
(N…O) 
2.03 
2.61 
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Chapter 4: Porcine Constitutive Androstane Receptor (CAR) - Identification 
of splice variants and its role in regulation of xenobiotic metabolism in an in 
vitro porcine model 
Abstract  
Constitutive androstane receptor (CAR) is a member of the nuclear hormone 
receptor superfamily of ligand-activated transcription factors and has been emerged 
as a key regulator of xenobiotic metabolism. The purpose of the present study was 
to identify and characterize novel splice variants of porcine CAR. A total of five novel 
transcript variants of CAR were detected. Molecular modeling studies with a 
synthetic ligand indicate a reduction of the binding affinity of the splice variants 
compared to the wild type proteins. Expression profiles of the splice variants in 
different porcine tissues were also investigated. The role of CAR in xenobiotic 
metabolism in an in vitro porcine model was investigated and it was found that CAR 
modulates expression of a number of cytochrome P450 enzymes to regulate the 
metabolism of xenobiotics. 
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Introduction 
Constitutive androstane receptor (CAR, NR1I3) has been emerged as a key 
regulator of drug and xenobiotic metabolism and disposition [1]. Together with other 
xenobiotic nuclear receptors, CAR senses xenobiotic ligands and activates phase I 
and phase II drug metabolizing enzymes and phase III transporters for elimination 
of the xenobiotics [2,3]. CAR was identified in 1994 as constitutively active nuclear 
receptor modulating retinoic acid signaling but the ligand and target genes were not 
known at that time [4,5]. Research in past decade has identified diverse xenobiotics 
including drugs, pesticides, environmental contaminants, industrial chemicals and 
many more as ligands of CAR [6]. Now, CAR has been established as a crucial 
sensor for xenobiotics [7]. CAR also plays important role in regulation of cellular 
homeostasis and metabolism of several endogenous compounds like steroids, bile 
acids, vitamin D, thyroid hormone and bilirubin [8]. As a typical nuclear receptor, 
CAR has N-terminal AF1 dommain, DNA-binding domain and ligand-binding domain 
(LBD) [1]. CAR forms heterodimer with retinoid X receptor (RXR) and binds to the 
xenobiotic response element (XRE) of its target gene [9]. Involvement of CAR in 
controlling of hepatic carbohydrate and lipid metabolism has been reported recently 
[10–13]. 
CAR is complexed with heat shock protein 90 and cytoplasmic retention protein 
in the cytoplasm in unexposed condition [14] and exposure to xenobiotics leads to 
nuclear translocation and activation of target genes. Phosphorylation and de-
phosphorylation play important role in regulating the nuclear translocation of CAR 
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[15] . The CAR gene is expressed in in tissues with high capacity of xenobiotic 
metabolism such as liver and intestine [1]. 
Alternative splicing, has been thought to be one of the major contributors of 
protein diversity, as it often results in the expression of protein isoforms [16]. It is 
also a common phenomenon in the nuclear receptor family. In human, alternative 
splicing has been reported in a number of nuclear receptors like Vitamin D receptor 
and pregnane X receptor and constitutive androstane receptor [17,18]. The objective 
of the present study was to identify and characterize transcript variants of porcine 
CAR and investigate the role of CAR in regulation of xenobiotic metabolism in an in 
vitro porcine model.  In this study we identified 5 novel transcript variants of CAR 
and investigated the properties of the transcript variants by molecular modeling 
studies. 
Materials and Methods 
Reagents 
All chemicals were purchased from Sigma-Aldrich (USA) unless stated 
otherwise. Cell culture plastics were from Midsci, USA. 
RNA Isolation and cDNA synthesis 
 Total RNA was isolated from porcine tissues using RNeasy Mini Kit (Qiagen) as 
per manufacturer’s protocol. RNA pellets were dissolved in nuclease-free water and 
stored at -80°C until analysis. Quality of the RNA was determined by using Nano 
Drop spectrophotometer. The concentration of the RNA was determined by Qubit® 
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RNA HS Assay Kit (Thermo Fisher Scientific, Life Technologies) as per 
manufacturer’s protocol.  
 Reverse transcription of RNA was performed from 1 µg total RNA in the 
presence of RNase inhibitor, random hexamer primers (50 ng/µl), deoxynucleotides 
(dNTPs, 10mM), SuperScript III reverse transcriptase (200 U/µl) and reverse 
transcriptase buffer in a 20 µl final reaction volume using SuperScript III First-Strand 
Synthesis System for RT-PCR kit (Invitrogen, Life Technologies, IN, USA). 
Cloning and sequencing of CAR gene 
 Based on the exonic regions of the porcine CAR (NR1I3) gene, cDNAs that 
together encode the complete ORF of both the genes were amplified using the 
primer sets (Table 4.1). PCR reactions were performed in a 25 µl reaction volume 
containing 50 ng cDNA as the template, 0.5 M of each primer, 2X PCR buffer 
(including 1.5 mM MgCl2), 200 mM dNTPs, and 0.625 units of Taq DNA polymerase. 
PCR reaction conditions were as follows: denaturation at 95 °C for 5 min, followed 
by 35 cycles of 95 °C for 30 s, 60°C for for 30 s, and 72 °C for 2 min, with a final 
extension at 72 °C for 20 min. Then, the 5′ and 3′ untranslated regions of CAR 
transcript from various tissues were amplified using total RNA and the 
FirstChoiceTM RNA ligase-mediated (RLM)-RACE kit (Ambion, Austin, TX). This 
procedure used primers supplied with the kit and the nested gene-specific primers 
listed in Supplementary Table 4.1. These products were cloned into pCRTOPO2.1 
vector and sequenced. The cDNAs and deduced amino acid sequences were 
analyzed using the Biology Workbench (http://workbench.sdsc.edu/).  
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Generation of 3-D structure of CAR and its splice variants through homology 
modeling 
In the absence of crystal structures of porcine CAR, we opted to develop 
homology model. The deduced amino acid sequences of CAR were analyzed by the 
Geneious R6 software (www.geneious.com). The query sequence was submitted in 
protein-protein BLAST (Basic Local Alignment Search Tool) program to find out the 
related protein structure with maximum sequence identity, highest score and least E-
value to be used as a template (http://www.ncbi.nlm.nih.gov/BLAST). The proteins 
(PDB ID: 1XNX) and was used as templates for CAR homology modeling. The 
sequences of the template proteins were retrieved from the protein data bank 
(www.rcsb.org).  
CAR transcript variant sequences were aligned and trimmed by Bioedit v7.2.5 
software (http://www.mbio.ncsu.edu/bioedit/bioedit.html). The short sequences as 
well as ambiguous alignments were removed. Further, the entropy values were 
predicted. All deduced protein sequences of CAR transcript variants were modeled 
using MODELLER v9.1 (http://salilab.org/modeller) program [19,20]. The sequence-
structure matches were established using a variety of fold assignment methods, 
including sequence-sequence, profile sequence, and alignments. Each model was 
evaluated using a multiple scoring algorithm that includes length of modeled 
sequence, identity of structure-sequence alignment, gap of alignment, compactness 
of model, and potential Z-scores. Representative models were ranked based on 
statistical potential value of Discrete Optimizes Potential Energy (DOPE) and the 
best one was selected.  
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Evaluation and validation of the3-D structures  
The final modeled structures were validated by Procheck [21] 
(http://services.mbi.ucla.edu/PROCHECK/). Procheck was used to perform full 
geometric analysis as well as stereochemical quality of protein structures. 
Ramachandran plot statistics was used to evaluate the stability of the models.   
Molecular docking analysis to investigate the interaction of LXRα, LXRβ and 
their splice variants with a synthetic ligand 
CITCO is a well-known synthetic ligand for CAR [22]. To gain an understanding 
of the molecular interactions during ligand binding, molecular docking analysis of 
CAR splice variants with a synthetic ligand CITCO was done. The chemical 
properties of CITCO are presented in Table 4.2. 
Protein and Ligand preparation 
Each modeled proteins were prepared using protein preparation wizard of 
Schrodinger LLC., Portland, USA (http://www.schrodinger.com). This adds 
hydrogen atoms charges, and does energy minimization of the structures using 
Impact Refinement module using OPLS (2005) force field.  The minimization was 
terminated when the energy converged or Root Mean Square Deviation (RMSD) 
reached a maximum cutoff of 0.03Å.  
The ligand CITCO (Figure 4.1) was obtained from Pubchem database 
(http://www.pubchem.com). This ligand was built with Chemsketch v12.0 (ACD 
Labs, USA; http://www.acdlabs.com), and the 3D structure was further energy 
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minimized by LigPrep program (Schrodinger suite LLC., Portland, USA) using the 
OPLS 2005 force field at pH 7.0 and keeping rest of the parameter values as default. 
The pharmacophore model was developed using PHASE 3D-QSAR software 
[23] which utilizes conformational sampling and other scoring parameters to identify 
the common 3D pharmacophore. The pharmacophore model of CITCO is presented 
in Figure 4.1. 
Molecular docking 
The molecular docking was carried out using Glide program [24] of the 
Schrodinger suite. Glide is designed to assist in high-throughput screening of 
potential ligand based on binding mode and affinity for a given receptor molecule. 
Glide provides three different level of docking precisions (HTVS, High-Throughput 
Virtual Screening; SP, Standard Precision; XP, Xtra Precision). The entire Glide 
program was run using default mode. Minimization cycle for conjugate gradient and 
steepest descent minimization were used with default value of 0.05 Å for initial step 
size and 1.0 Å for maximum step size. In the coincide criteria for minimization, both 
the energy change criteria and gradient criteria were used with default value of 10-7 
and 0.001 kcal/mol respectively. All conformations were considered for docking and 
in the docking process the Glide score was used to select the best conformation for 
the ligand.  
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Effects of CITCO on transcript expression CAR and genes involved in phase 
I, Phase II drug metabolism, phase II transport and nuclear receptors 
 CAR is a well-documented potent synthetic agonist of CAR [22]. To gain insight 
into the role of CAR in porcine xenobiotic metabolism, the effect of the synthetic 
ligand on the expressions of the most important drug metabolism and regulation 
genes in porcine primary hepatocytes were investigated.   
Cell culture and treatments 
Primary hepatocytes were isolated by using a simplified manual perfusion 
method. Immediately after the animal was euthanized, a single liver lobe was 
resected, washed 2-3 times with ice cold phosphate buffer saline and transported to 
the laboratory in ice cold Krebs Ringer Solution. Then the liver sample was 
cannulated with suitable pipette into visible blood vessels on the cut surface and was 
flushed with 500 ml of buffer A containing 8.3 g/l NaCl, 0.5 g/l KCl, 2.4 g/l HEPES 
and 0.19 g/l EGTA at pH 7.4 and 37°C. This was followed by perfusion of 500 ml 
buffer B containing 8.3 g/l NaCl, 0.5 g/l KCl and 2.4 g/l HEPES. Continuous 
recirculating perfusion was then carried out on the tissue using a pre-warmed 
digestion buffer (Buffer C) solution containing 3.9 g/l NaCl, 0.5 g/l KCl, 2.4 g/l 
HEPES, 0.7 g/l CaCl2 X 2H2O and 0.1 % collagenase (type IV). Following sufficient 
digestion, the liver capsule was removed and dissolved cells were liberated by gentle 
shaking of the liver specimen in ice cold buffer D containing 9.91 g/l Hanks buffered 
salt without calcium and magnesium, 2.4 g/l HEPES and 2.0 g/l bovine serum 
albumin. A scalpel was used to cut through the regions which were not well perfused 
to release cells contained within. The resulting cell suspension was filtered through 
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a nylon mesh with 100 µm pore size and centrifuged at 50 g for 3 min at 4°C. After, 
we employed a cell incubation step for 10 min with DNase1 containing buffer at 4°C 
during which cell clumps were broken and damaged cells digested. Then the 
resulting suspension was filtered through 70 µm nylon mesh and cells were 
harvested by 50 g for 3 min. This was followed by three washing in ice cold buffer 
D. The resulting cell clumps were finally re-suspended in culture medium (William’s 
E supplemented with 100 mU/ml penicillin, 100 µg/ml streptomycin, 2mM glutamate 
and 10% Fetal bovine serum). Viability of hepatocytes was determined by trypan 
blue dye exclusion test [25]. 
Freshly isolated hepatocytes were cultured in William’s E medium 
supplemented with 100 mU/ml penicillin, 100 µg/ml streptomycin, 2 mM glutamate 
and 10% fetal bovine serum. Prior to experiments, cells were washed twice with PBS 
followed by incubation in medium containing CITCO. 
Real time PCR 
Total RNA isolation and cDNA synthesis have been done as described 
previously. Relative quantification of the genes involved in phase-I, phase-II drug 
metabolism, phase III transport and  nuclear receptors was performed by using 
Power SYBR green PCR Master Mix (2X) (Applied Biosystems) in Taqman ABI 7900 
Real-Time PCR system (Applied Biosystems). The thermal cycling conditions for 
real-time PCR were one cycle of 50 °C for 2 min (AmpErase uracil-N-glycosylase 
activation) and 95°C for 10 min (AmpliTaq Gold activation), followed by 40 cycles of 
95°C for 15 sec (denaturation) and 60°C for 1 min (annealing and extension).The 
housekeeping genes GAPDH and ACTB were used as endogenous control to 
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normalize for RNA loading or differences in reverse transcription efficiency. The 
information on the primers is presented in Table 4.2. The relative expression levels 
were calculated with respect to the normalized expression of the controls by delta 
delta Ct (ΔΔCt) method. 
Results 
Identification of novel transcript variants of porcine CAR 
Total five novel CAR transcript variants (CAR-2 to Car-6) were detected in 
different porcine tissues (Figure 4.2).  CAR-1 (wild type) transcript consists of eight 
exons which code for 348 amino acids. CAR-2 had deleted exon 6 during splicing. 
CAR-3 had a twelve nucleotide insert between exon 5 and exon 6. CAR-4 had a 
nine nucleotide insert between exon 3 and exon 4 and exon 6 were missing.  Exons 
3, 4 and 5 were missing in CAR-5, whereas exons 3, 4, 5 and 6 were missing in 
CAR-6. The physiochemical properties of the deduced amino acids of the CAR 
transcript variants are presented in Table 4.4. 
 The expression of the different variants are indicated in the Figure 4.2. The wild 
type was detected in all the tissues screened. CAR-2 was detected in kidney, small 
intestine, and spleen.  CAR-3 was detected in liver, small intestine and spleen. CAR-
4 was detected in only liver. CAR-5 and CAR-6 were detected in only kidney 
Reduced binding affinity of the novel transcript variants of porcine CAR 
towards ligand (CITCO) compared to the wild type protein 
In the absence of a crystal structure for porcine CAR, we opted to develop 
homology model for porcine wild type CAR (Figure 4.4F) and the identified transcript 
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variants (Figure 4.4A-E). Wild type CAR ligand binding domain contain 11 α-helices 
and 3 short β-strands and the ligand binding pocket is made up of by helices 2-7 
and 10 and three β-sheets which is consistent with human [22,26].The molecular 
interactions of CAR transcript variants with synthetic ligand CITCO are presented in 
Figure 4.5 to Figure 4.8. The binding affinity, interacting amino acids in LBD, and 
hydrogen bond distance of different CAR transcript variants with CITCO is presented 
in Table 4.5. The results showed that the wild type protein CAR-1 has the highest 
binding affinity (Glide score of -11.0 Kcal/mol) towards its ligand. The other transcript 
variants had reduced binding affinity for the synthetic ligand. CAR-4 and CAR-5 did 
not show any binding affinity towards the ligand. The three dimensional 
conformations of the novel splice variant proteins have been changed due to 
splicing. The disturbed 3-D conformation may be the reason behind the reduction in 
the binding affinity towards the ligand. 
CAR agonist modulates the expression of genes involved in xenobiotic 
metabolism in porcine primary hepatocytes 
To gain understanding how CAR is involved in xenobiotic metabolism pathways, 
we induced CAR by addition of the synthetic ligand CITCO and studied the 
expression of the key genes involved in xenobiotic metabolism and its regulation. 
We treated primary hepatocytes with CITCO to activate CAR and studied the 
expression of phase-I, phase-II drug metabolism genes and phase-III transporters 
to understand the involvement of CAR in xenobiotic metabolism pathways. 
Treatment of CITCO upregulated CAR transcript expression in porcine primary 
hepatocytes (Figure 4.9) indicating that CITCO is a good agonist for porcine CAR. 
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Treatment of CITCO caused a significant increase of CYP2B22, CYP2C33, 
CYP2C42 and CYP3A; all the other CYPs remain unchanged (Figure 4.10). Phase 
II drug metabolism genes SULT1A1 and GSTO1 were upregulated following CITCO 
treatment. Among nuclear receptors studied, ABCB1 and ABCC2, were upregulated 
(Figure 4.10).  From the results of the study, it can be concluded that activated LXRs 
induce the expression of CYP2B22, CYP 2C33, CYP2C42, CYP3A and the 
transporters (ABCB1 and ABCC2). 
Discussion 
Nuclear receptors are master regulators of a wide variety of metabolism 
including endogenous metabolites and exogenous xenobiotics that integrate the 
homeostatic control of almost all biological processes [27]. Nuclear receptors 
regulate transcription through the recruitment of coactivator proteins to the ligand 
binding domain (LBD) [28].  
Exons 2 and 3 and part of exon 4 encode the DNA binding domain (DBD) and 
the hinge regions, whereas the ligand binding domain (LBD) is encoded by the rest 
of exon 4 and exon 5 to exon 9. In the present study, five novel splice variants of 
CAR were identified. The splice variants had truncated amino acids in the protein 
sequences (Table 4.4). At least 26 splice variants has been reported in human, most 
of which codes for a premature stop codon or code for a truncated protein [29,30]. 
Due to changes in the LBD structures, differences in ligand binding affinity has been 
reported between human wild-type CAR and isoforms [31,32]. In the present study 
also, a reduction in the binding affinity was found in splice variants (CAR-2, CAR-3 
and CAR-4) towards a synthetic ligand (Table 4.5). Two identified splice variants 
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(CAR-5 and CAR-6) did not bind at all to the synthetic ligand CITCO. In CAR-5, 
exons 4, 5 and 6 was deleted and in CAR-6, exons 4, 5, 6 and 7 was deleted. As 
exons exons 4, 5 and 6 form the ligand binding domain for the wild type CAR, 
deletion of these impairs the binding of the ligand. 
To gain understanding on how LXRs are involved in the xenobiotic metabolism 
pathways, we induced LXRs by addition of synthetic ligands and studied the 
expressions of the most important genes involved in xenobiotic metabolism and its 
regulation. Treatment of CITCO caused a significant increase of CYP2B22, CYP 
2C33, CYP2C42, and CYP3A among phase I drug metabolism enzymes, SULT1A1 
and GSTO1 among phase II enzymes and ABCB1 and ABCC2 among transporters 
(Figure 4.10). In human, the hepatic induction of phase I (e.g. CYP2B6, CYP2C9, 
CYP3A4) and phase II (e.g. UGT1A1, GSTA1) drug metabolizing enzymes and of 
transporters (e.g. MRP2, SLC21A6) by CAR in response to structurally diverse 
chemicals has been reported [33,34]. 
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Figures and Tables 
 
Figure 4.1. Chemical structure of CITCO 
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Figure 4.2. Identified transcript variants of CAR 
The tissue distribution of the splice variants are indicated in the right side.  
Li, Liver; K, Kidney; S.I, Small Intestine; Sp, Spleen 
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Figure 4.3. Multiple sequence alignment of CAR transcript variants 
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Figure 4.4. 3D structure of porcine CAR splice variants by homology modeling 
A, CAR-2; B, CAR-3; C, CAR-4; D, CAR-5; E: CAR-6; F, CAR-1 
H denotes helix and S denotes β-sheet 
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Figure 4.5. Molecular modeling interactions of CAR-1 with CITCO 
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Figure 4.6. Molecular modeling interactions of CAR-2 with CITCO 
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Figure 4.7. Molecular modeling interactions of CAR-3 with CITCO 
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Figure 4.8. Molecular modeling interactions of CAR-4 with CITCO 
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Figure 4.9. Effect of CITCO on expression of CAR transcript in primary porcine hepatocytes 
Real time RT-PCR was performed to analyze the effect of CAR ligand CITCO (10 µM) on 
expression of CAR transcript in primary hepatocytes. The values and error bars represent 
average and standard deviations of three independent set of experiments. One-way analysis 
of variance (ANOVA) followed by Dunnett post-test was performed to find out significant 
difference among control and treatments. *** denotes p≤0.001 
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Figure 4.10. Effect of CITCO on expression of phase-I, phase-II and Phase-II DME 
transcripts 
Real time RT-PCR was performed to analyze the effect of CAR ligand CITCO (10 µM) on 
expression of the most important genes involved in regulation of drug metabolism. The 
values and error bars represent average and standard deviations of three independent set 
of experiments. One-way analysis of variance (ANOVA) followed by Dunnett post-test was 
performed to find out significant difference among control and treatments. * denotes p≤0.05; 
** denotes p≤0.01; *** denotes p≤0.001; **** denotes p≤0.0001. 
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Table 4.1 
 
 
 
 
 
 
 
Table 4.1. Cloning and RACE primers for CAR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cloning Primers 
CAR Forward TGAAGGCCACAGAGGTAGAAGTTCCTTG 
CAR Reverse AGCAGCGGCATCATGGTGGACAGTCC 
RACE Primers 
3’RACE-outer  Supplied with kit 
CAR 3' OUTER TAAGACACTTCGGCGACTGC 
3’RACE-inner  Supplied with kit 
CAR 3' INNER TCTCCGGGACAGGTTTCTCT 
5’RACE-outer  Supplied with kit 
CAR 5' OUTER  CTTGCAGCCCTCACAAGTCAAG 
5’RACE-inner Supplied with kit 
CAR5' INNER  CCGCACACAGCACAGTTCCTTG 
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Table 4.2 
Molecular Weight 436.74208 g/mol 
XLogP3 7.3 
Hydrogen Bond Donor Count 0 
Hydrogen Bond Acceptor Count 4 
Rotatable Bond Count 5 
Exact Mass 434.976666 g/mol 
Monoisotopic Mass 434.976666 g/mol 
Topological Polar Surface Area 67.1 A^2 
Heavy Atom Count 27 
Formal Charge 0 
Complexity 520 
Isotope Atom Count 0 
Defined Atom Stereocenter Count 0 
Undefined Atom Stereocenter Count 0 
Defined Bond Stereocenter Count 1 
Undefined Bond Stereocenter Count 0 
Covalently-Bonded Unit Count 1 
 
Table 4.2. Chemical properties of CITCO 
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Table 4.3 
Gene Name Primers Sequences (5’-3’)  
GAPDH 
 
Forward GGCAAATTCCACGGCACAGTCA 
Reverse CTGGCTCCTGGAAGATGGTGAT 
 ACTB 
 
Forward GCAAATGCTTCTAGGCGGACTGT 
Reverse CCAAATAAAGCCATGCCAATCTCA 
Porcine 
Albumin 
 
Forward TGGTGACTTGGCTGACTGCTG 
Reverse TGTCGGGGTTATCATTTTTGTGTTG 
HNF4A 
 
Forward AGTCCCAGAGTGGTAGTGGAAAG 
Reverse CAGATGGTGAAGGGTGGCATTG 
G6PC 
 
Forward ATTGAAAGACGATGACTGTGCCAA 
Reverse CAAAGGAGGAAGGAGTTCTGAGC 
CYP1A1 
 
Forward AAGAGGCAGAGGTGAAGTGGTGAA 
Reverse GAGAAGAAGGAAGGCAGTGAAGTGATAG 
CYP1A2 
 
Forward ACACCTTCTCCATTGCCTCAGACC 
Reverse GCACTCAGCCTCCTTGCTCAC 
CYP2A19 
 
Forward CCGAAGAGTCACCAAGGATACCAAG 
Reverse ACAGAGCCCAGCATAGGGAACA 
CYP2B22 
 
Forward CAGATGAGTAAACAGAGCCCGAGAA 
Reverse CGAGAGCCAAGGAGACAGCA 
CYP2C33 
 
Forward TGGAAGAAAAATCACAAGAGGAGAAGG 
Reverse TTGGAAAGAGACGCAGGGATGT 
CYP2C42 
 
Forward TACAGAGACAACAAGCACCACCA 
Reverse CTGCCAATCACACGGTCAATC 
CYP2C49 
 
Forward CTTGTGGAGGAGTTGAGAAAAACC 
Reverse TTGTGGAAAATGATGGAGCAGA 
CYP2E1 
 
Forward ACACCCTGCTGATGGAAATGGA 
Reverse GTGGTCTCTGTCCCCGCAAA 
CYP3A 
 
Forward TACCTGCCCTTTGGGACTGGAC 
Reverse AGTTCTGCAGGACTCTGACGA 
CYP7A1 
 
Forward TTCTGCTACCGAGTGATGTTTGAGG 
Reverse AGGTTGTTTAGGATGAGTGCTTTCTGTG 
SULT1A3 
 
Forward GACCACAGCATCTCAGCCTTCAT 
Reverse CTGCCATCTTCTCAGCATAGTCG 
SULT2A1 
 
Forward AAATGCTGCAAGAGGTGAGGGAGG 
Reverse ATCCCCCTTGGAGAGAATCAGGCA 
SULT1E1 
 
Forward GAGAAAGGGGATTGCAGGAGACTG 
Reverse GTAGACCCCTTCATTTGCTGCTCA 
GSTO1 
 
Forward GAGATTCTGTCCTTTCGCCCAGAG 
Reverse GATGACTTGATGCCGGATTCCCTT 
GSTK1 
 
Forward GGTACACCATCCACCGTTAGTCTC 
Reverse CACACAAACACCAGCAAAGACACA 
ABCB1 
 
Forward TGGCAGTGGGACAGGTTAGTTC 
Reverse CACGGTGCTTGAGCTGTCAATC 
ABCB6 
 
Forward TGTTGTCCCAAGGTGGTGTGTATG 
Reverse GCTGAAATGGATTTCCCTCCAGGT 
ABCC2 
 
Forward GTGGCTGTTGAGCGAATAAATGAATAC 
Reverse TGCTGGGCCAACCGTCTG 
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Table 4.3 (cont.) 
Gene Name Primers Sequences (5’-3’)  
ABCC3 
 
Forward TGATGCAGACGCTGATCTTACACC 
Reverse ACTCACGTTTGACGGAATTGGTGA 
ABCG2 
 
Forward GATCTTTTCGGGGCTGTTCCTCA 
Reverse TGAGTCCCGGGCAGAAGTTTTGT 
PXR 
 
Forward GACAACAGTGGGAAAGAGAT 
Reverse CCCTGAAGTAGGAGATGACT 
FXR 
 
Forward CATTCAACCATCACCACGCAGAGA 
Reverse GCACATCCCAGACTTCACAGAGA 
CAR 
 
Forward GAAAGCAGGGTTACAGTGGGAGTA 
Reverse CTTCAGGTGTTGGGATGGTGGTC 
LXRA 
 
Forward TCCAGGTAGAGAGGCTGCAACATA 
Reverse AGTTTCATTAGCATCCGTGGGAAC 
LXRB 
 
Forward GAGTCTTCCTGAGAGGGGCAGATA 
Reverse CGTGGTAGGCTTGAGGTGTAAGC 
PPARA 
 
Forward AATAACCCGCCTTTCGTCATACAC 
Reverse GACCTCCGCCTCCTTGTTCT 
PPARG 
 
Forward CCATGCTGTCATGGGTGAAACTCT 
Reverse GTCAACCATGGTCACCTCTTGTGA 
RXRA 
 
Forward CCTTCTCGCACCGCTCCATA 
Reverse CGTCAGCACCCTGTCAAAGATG 
RXRG 
 
Forward CTTCCCGTTCCCCAAACGTGAT 
Reverse CTTCCAGAAAAGATCCCCAGTCCC 
 
Table 4.3. Primer sequences for real-time PCR 
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Table 4.4 
Name Protein 
length 
Molecular Weight 
(kDa) 
Isoelectric 
Point 
CAR-1 348 39.809 8.72 
CAR-2 309 35.200 8.96 
CAR-3 352 40.233 8.71 
CAR-4 312 35.585 9.23 
CAR-5 196 22.421 8.41 
CAR-6 157 17.810 8.86 
 
Table 4.4:  Physiochemical properties of transcript variants of CAR 
 
 
 
 
 
 
 
 
 
 
 
 
 
123 
 
Table 4.5 
 
 
 
 
 
Table 4.5: Molecular Docking interactions of CAR transcript variants with its ligand CITCO 
GScore indicates Glide Score; AA indicates amino acid name; HB indicates hydrogen bond. 
 
 
 
 
 
 
 
 
 
 
 
Ligand 
Name 
G_Score 
(Kcal/mol) 
 
AA-
Name 
 
Interaction 
Atom 
HB-
distance 
(Å) 
CAR1(WT) -11.0 ASN165 PHE161 
N-H 
pi-pi 3.2 
CAR2 -6.2 PHE161 pi-pi 3.4 
CAR3 -9.2 ASN165 N-H 3.6 
CAR4 -6.6 PHE164 pi-pi 3.5 
CAR5 - - - - 
CAR6 - - - - 
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Chapter 5: Development of an in vitro porcine model for drug metabolism and 
toxicity assessment 
Abstract 
To date, in vitro cytotoxicity assays are not highly predictive of in vivo toxicity. 
There is a critical need for more predictive and reliable in vitro testing methods. Due 
to its physiological similarities with humans, pigs have emerged as a suitable and 
reliable animal model for pharmacological and toxicological studies. To further the 
pigs’ suitability, we have developed and characterized a transformed porcine 
hepatocyte cell line (pHCC) to support drug toxicity and metabolism assessments. 
Porcine primary hepatocytes had similar morphology to human and expression 
values of the most important drug metabolism genes involved in phase I and II drug 
metabolism, phase-III transport were comparable to human primary hepatocytes. 
However, primary hepatocytes have a limited life span in culture and usually within 8 
days post culture more than 50% of cells undergo apoptosis. Moreover, normal gene 
expression declines from day 5 in culture. To overcome these limitations, we have 
generated and characterized transformed hepatocyte cell lines (pHCC) derived from 
the transgenic Oncopig. Three independent hepatocyte cell lines were developed 
from three different Oncopigs and all of them expressed hepatocyte specific and most 
important drug metabolism and regulation genes comparable to those porcine 
primary hepatocytes. We evaluated the effect of selective CYP modulators on three 
pHCC and pPH cell lines. All the three independent pHCC cell lines behaved the 
same way and the gene regulation pattern in pHCC was similar to that of primary 
hepatocytes and human models. Exposure of pHCC cells to hepatotoxic drugs 
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caused a concentration-dependent decrease in cell viability comparable to those of 
human models. These findings indicate that this porcine hepatocyte cell line 
represents a useful and predictive model for high throughput screening of new drugs 
as well as studies on metabolism and hepatotoxicity of chemicals. 
Introduction  
Major reasons that contribute to the failure of a drug in preclinical and clinical 
studies are toxicity and efficacy. The adverse effects of new drugs are often not 
discovered until preclinical animal safety studies or even clinical trials; 40% of drugs 
fail in preclinical animal studies and 89% of those that reach clinical trials fail [1].  
There is a critical need for more predictive and reliable in vitro testing methods. A 
good in vitro model can identify issues related to toxicity early in the discovery 
process thereby saving millions of dollars.  
Metabolism of a drug or xenobiotics is critical for its pharmacokinetic properties, 
and the liver is the main organ of drug or xenobiotics biotransformation (Lübberstedt 
et al., 2011; Tuschl et al., 2009). The cytochrome P450 (CYP) isozymes expressed 
in the hepatic tissue constitute the major enzyme family capable of catalyzing the 
oxidative biotransformation of most drugs and lipophilic xenobiotics [4]. Primary 
human hepatocytes are considered the standard model for drug metabolism and 
toxicity studies as they provide a complete picture of the metabolic fate of xenobiotics 
in vitro (Lübberstedt et al., 2011; Brandon et al., 2003). However, primary human 
hepatocytes have limited availability and undergo early and variable phenotypic 
alterations in culture [5]. Most of the human liver cell lines have poor or fractional 
CYP expression [4,6,7]. To date, the lack of a reliable animal model for assessment 
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of drug toxicity and metabolism is a major limitation in early high throughput screening 
of xenobiotics.  Immunological and physiological differences between rodents and 
humans represent major constraints for the use of rodent-based models in drug 
screening. Therefore, a large animal model surrogate for human hepatocytes is a 
very important improvement over the current methods for early screening of novel 
drugs and xenobiotics. 
 Over the years, the pig has gained increasing importance as a biomedical model 
due to similarities in size, anatomy and physiology with humans [8–10]. CYP 
enzymes have been extensively studied in pigs and enzymes equivalent to human 
P450 (eg. CYP1A, 2A6, 2E1, 3A4) have been identified in pig liver [11–13].  The 
sequence identity between human and porcine P450 enzymes is striking, ranging 
from 72 to 95 % [13]. Biotransformation data indicate that the CYP1A, 2A and 3A 
enzyme systems seem to be functionally very similar between pigs and humans 
[14,15]. In addition, the characterization of the porcine pregnane X receptor [16] and 
farnesoid X receptor [17] has been reported. In the present study, we developed and 
characterized a porcine hepatocyte cell line (pHCC) to be utilized for screening drug 
toxicity and metabolism assessment. 
Materials and Methods 
Reagents 
All chemicals were purchased from Sigma-Aldrich (USA) unless stated 
otherwise. Cell culture plastics were from Midsci, USA. 
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Animals 
All animal studies and procedures were approved by The University of Illinois 
Institutional Animal Care and Use Committee (IACUC; Protocol number 11221). 
Transgenic Oncopigs carrying Cre recombinase inducible transgenes encoding 
KRASG12D and TP53R167H, which represent a commonly mutated oncogene and tumor 
suppressor in human cancers [18], were utilized for experiments described here.  
Porcine hepatocyte isolation and culture 
Porcine primary hepatocytes (pPH) were isolated from three Oncopigs (Pig no 
316, 326 and 327) and were denoted as pPH1, pPH2 and pPH3. The modified 
procedure of Meng’s method [19] utilizing manual perfusion along with enzymatic 
digestion was used to isolate functionally viable hepatocytes from a single lobe of 
Oncopig liver. Immediately after the animal was euthanized, a portion of the liver lobe 
was resected, washed 2-3 times with ice cold PBS and transported to the laboratory 
in ice cold Krebs Ringer Solution. Then the liver sample was cannulated with a 
suitable pipette into visible blood vessels on the cut surface and flushed with 500 mL 
of buffer A containing 8.3 g/L NaCl, 0.5 g/L KCl, 2.4 g/L HEPES and 0.19 g/L EGTA 
at pH 7.4 and 37°C. This was followed by perfusion of 500 mL buffer B containing 8.3 
g/L NaCl, 0.5 g/L KCl and 2.4 g/L HEPES. Perfusion was then carried out on the tissue 
using a pre-warmed (37 °C) digestion buffer (Buffer C) containing 3.9 g/L NaCl, 0.5 
g/L KCl, 2.4 g/L HEPES, 0.7 g/L   CaCl2 X 2H2O and 0.1 % collagenase (type IV). 
Following digestion, the liver capsule was removed and dissolved cells were liberated 
by gentle shaking of the liver specimen in ice cold buffer D containing 9.91 g/L HBSS 
(without calcium and magnesium), 2.4 g/L  HEPES and 2.0 g/L BSA. A scalpel was 
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used to cut through the regions which were not well perfused to release cells 
contained within. The resulting cell suspension was filtered through a nylon mesh 
with 100 µm pore size and centrifuged at 50 X g for 3 min at 4°C. After, cells were 
incubated in DNase1 containing buffer at 4°C for 10 min to digest cell clumps. Then 
the resulting suspension was filtered through 70µm nylon mesh and cells were 
harvested by centrifugation at 50 X g for 3 min. This was followed by three washing 
in ice cold buffer D. The resulting cell clumps were finally re-suspended in culture 
medium (William’s E supplemented with 100 mU/mL  penicillin, 100 µg/mL 
streptomycin, 2 mM glutamate and 10% FBS). Viability of hepatocytes was 
determined by trypan blue dye exclusion test [20]. 
Freshly isolated hepatocytes were cultured in William’s E medium supplemented 
with 100 mU/mL  penicillin, 100 µg/mL  streptomycin, 2 mM glutamate and 10% FBS 
in either collagen coated or uncoated flask.  
Collagen coating 
A final concentration of 1.5 mg/mL rat tail collagen I in DMEM was used for the 
coating of flasks. The pH of the collagen was adjusted to 7.4 using DMEM. A volume 
of 1 mL was used for a 25 cm2 (T25) flask and dried overnight in a tissue culture 
hood.  Approximately, 2 X 106 cells were seeded with 5 mL of culture medium into a 
T25 culture flask. Five hours following seeding, culture medium along with 
unattached cells were removed and replaced with fresh medium. Medium were 
replaced with fresh medium every 24 h.  
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Cell viability and cell proliferation of hepatocytes 
The MTT assay was used to assess hepatocyte growth in culture. The reduction 
of tetrazolium salts is now widely accepted as a reliable way to examine cell 
proliferation. The yellow tetrazolium MTT (3-(4, 5-dimethylthiazolyl-2)-2, 5-
diphenyltetrazolium bromide) is reduced by metabolically active cells, in part by the 
action of dehydrogenase enzymes, to generate reducing equivalents such as NADH 
and NADPH. The resulting intracellular purple formazan can be solubilized and 
quantified by spectrophotometric means. For the MTT assay, hepatocytes were 
seeded in a 96 well plate at a density of 104 cells/100 µL/well. The MTT assay was 
done by incubating 100 µl MTT reagent (1 mg/mL) per well for 4 h at 37° C. After 4 
h, the formazan crystals were dissolved by adding 100 µL of DMSO. Then the optical 
density was measured at 570 nm in a microplate reader (SpectraMax Plus, Molecular 
Devices, USA). 
Apoptosis assay 
 The FITC Annexin V/Dead Cell Apoptosis Kit (Invitrogen, Life Technologies, 
USA) was used for the measurement of apoptosis. In normal live cells, 
phosphatidylserine (PS) is located on the cytoplasmic surface of the cell membrane. 
However, in apoptotic cells, PS is translocated from the inner to the outer leaflet of 
the plasma membrane, thus exposing PS to the external cellular environment [21]. 
The human anticoagulant, annexin V, is a 35–36 kDa Ca2+-dependent phospholipid- 
binding protein that has a high affinity for PS [22]. Annexin V labeled with a 
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fluorophore can identify apoptotic cells by binding to PS exposed on the outer leaflet 
[23]. Flow cytometric quantification of hepatocyte apoptosis was performed on day 1, 
3, 5, 8 and 15 of culture.  In brief, the cells were harvested, washed in PBS and 
stained with Annexin V-FITC and propidium iodide. The cells were incubated at room 
temperature for 15 min and fluorescence measured by flow cytometry (BD LSR II 
Flow Cytometer, BD Biosciences, USA). The data was analyzed using FCS Express 
4 software. 
Ad-Cre activation of the Oncopig primary Hepatocytes 
 Oncopig [18] hepatocytes were isolated and cultured as described above. On 
day 2 of culture, the medium was changed to low serum (5% FBS) and Ad5CMVCre-
eGFP recombinase (AdCre; University of Iowa Vector Core) was added at multiplicity 
of infection (MOI) of 200 to 500 as previously described [18]. Cells were incubated 
for 5 h at 37° C, after which AdCre medium was removed and replaced with fresh 
medium (10% FBS). Three hepatocyte cell lines (pHCC1, pHCC2 and pHCC3) were 
developed. The hepatocyte cell lines (pHCCs) were passed after reaching 80% 
confluence. The expression of transgenes (KRASG12D and TP53R167H) was 
determined by RT-PCR as described by [18].  
Doxorubicin sensitivity assay 
Doxorubicin sensitivity of the pPH and pHCC cell lines was determined by MTT 
assay. Cells were seeded in 96-well plates (1 X 104 cells/well) in William’s E medium 
with 10% FBS. 24 h after plating, the cells were treated with doxorubicin (0-4 µg/mL) 
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and incubated for 72 h at 37° C in an atmosphere of 5% CO2. Untreated pHCC cells 
were used as control. The MTT assay protocol was followed as described above.  
 
DMSO treatment of the pHCC cells 
 pHCC cells were seeded at low density (2 X 104 cells/cm2) in supplemented 
William’s E (10% FBS, 100 mU/mL penicillin, 100 µg/mL streptomycin, 2 mM 
glutamate). At confluence, the medium was supplemented with 2% DMSO. The 
medium was changed every 2-3 days. The cells were cultured in presence of DMSO 
for 15 days before using for further experiments. 
RNA Isolation  
 Total RNA was isolated from pPH and pHCC cell lines (cultured in presence or 
absence of DMSO) using RNeasy Mini Kit (Qiagen) as per the manufacturer’s 
protocol. RNA pellets were dissolved in nuclease-free water and stored at -80°C until 
analysis. Quality of the RNA was determined using NanoDrop spectrophotometer 
and analyzed by an Agilent 2100 Bioanalyzer to determine RNA integrity as well as 
the presence/absence of gDNA by the Carver High-Throughput DNA Sequencing 
and Genotyping Unit (HTS lab, University of Illinois, Urbana, IL, USA). The 
concentration of the RNA was determined by Qubit® RNA HS Assay Kit (Thermo 
Fisher Scientific, Life Technologies) as per manufacturer’s protocol. 
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RT-PCR 
 Reverse transcription of RNA was performed from 1 µg total RNA in the presence 
of RNase inhibitor, random hexamer primers (50 ng/µL), deoxynucleotides (dNTPs, 
10 mM), SuperScript III reverse transcriptase (200 U/µL) and reverse transcriptase 
buffer in a 20 µL final reaction volume using SuperScript III First-Strand Synthesis 
System for RT-PCR kit (Invitrogen,Life Technologies, IN, USA). PCR reactions were 
performed in a 25 µl reaction volume containing 50 ng cDNA as the template, 0.5 M 
of each primer, 2X PCR buffer (including 1.5 mM MgCl2), 200 mM dNTPs, and 0.625 
units of Taq DNA polymerase. The PCR primer sequences and PCR conditions are 
given in table 5.1.   
Quantitative RT-PCR 
 Reverse transcription of RNA was performed as stated above. Relative 
quantification of the genes was performed by using Power SYBR green PCR Master 
Mix (2X) (Applied Biosystems) in a Taqman ABI 7900 Real-Time PCR system 
(Applied Biosystems).  Information on primer used are listed in Table 5.2. The thermal 
cycling conditions for real-time PCR were one cycle of 50 °C for 2 min (AmpErase 
uracil-N-glycosylase activation) and 95°C for 10 min (AmpliTaq Gold activation), 
followed by 40 cycles of 95°C for 15 sec (denaturation) and 60°C for 1 min (annealing 
and extension).The housekeeping genes GAPDH and ACTB were used as 
endogenous controls to normalize for RNA loading or differences in reverse 
transcription efficiency. Gene expression levels were calculated using the 2-ΔΔCt 
method relative to the internal control. 
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Evaluation of the effect of selective CYP modulators  
 The effects of selective CYP modulators on the expression of a number of drug 
metabolism enzymes (DMEs) in pPH and pHCC cells (+DMSO) were evaluated. The 
compounds were well-documented selective modulators of CYPA1/2 (3-
methylcholanthrene), CYP3A (Rifampicin) and CYP2A6, CYP2B6, CYP3A 
(Phenobarbital) [24]. Porcine primary hepatocytes (day 1 of culture) and pHCC cells 
(pass 8) were exposed to 2 µM 3-methylcholanthrene or 1 mM phenobarbital or 50 
µM rifampicin in separate experiments. The culture medium was removed and 
replaced with serum free medium containing test compound and incubated for 24 h. 
The mRNA levels corresponding to major drug metabolizing porcine P450 enzymes 
were measured by quantitative RT-PCR. 
Evaluation of drug cytotoxicity 
 The effects of four reference hepatotoxic drugs, namely Aflatoxin B1 (AFB1), 
amiodarone, chlorpromazine and acetaminophen were evaluated on porcine primary 
hepatocytes (day 1 of culture) and pHCC cell lines cultured in presence of DMSO at 
two different passages (8th and 15th) at 72 h after exposure. Incubations were 
performed with medium free from DMSO and FBS. At the end of the incubation time, 
the MTT assay was performed as described above.  
Statistical analysis  
 Data are expressed as mean ± SD. Statistical significance was evaluated by 
using one-way analysis of variance (ANOVA) followed by Dunnett post-test or by 
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using a paired student’s t test (two-tailed). Differences were considered significant 
when p ≤ 0.05. All data was analyzed by Graphpad-prism 6.  
Results 
Porcine hepatocytes display similar morphology to human hepatocytes, are 
epithelial in origin, and express hepatocyte specific functional genes 
 To determine whether porcine hepatocytes have similar morphology to humans, 
the morphology of freshly isolated and cultured Oncopig hepatocytes were observed. 
The freshly isolated viable hepatocytes were bright, translucent and spherical in 
shape. After 24 h of culture, the hepatocytes had attached, aggregated into clusters 
and established cell-cell interactions. The arrangement showed typical liver 
morphological appurtenance with polygonal cells, containing granular cytoplasm and 
two or more nuclei (Figure 5.1A). The morphology of the cultured hepatocytes was 
similar to that of human [25]. Immunohistochemistry showed that the cells were 
positive for cytokeratin (Figure 5.1B) and negative for vimentin (Figure 5.1C) which 
indicates that they are epithelial in origin. Further characterization showed that each 
of the three primary hepatocyte cell lines examined expressed the hepatocyte 
specific genes albumin (ALB), glucose-6-phosphatase (G6PC) and hepatocyte 
nuclear factor 4 alpha (HNF4A) (Figure 5.3).  
Relative abundance of drug metabolizing enzyme genes in porcine primary 
hepatocytes is consistent with human primary hepatocytes 
 Relative abundance of the most important drug metabolism enzyme genes in the 
porcine primary hepatocytes (Day 1 of culture) isolated from three different pigs was 
141 
 
investigated by quantitative PCR. Expression value of the genes was calculated 
based on the assumption that average expression level of two housekeeping genes 
GAPDH and ACTB is 1. The results are presented in table 5.3. The expression values 
of the DME genes were similar in all the three porcine primary hepatocytes and 
comparable to those of human primary hepatocytes reported by Guo et al., 2011 [7]. 
Among the phase I DMEs, CYP2C49, CYP2C33, CYP3A and CYP1A2 transcripts 
were highly abundant. GSTO1 was the most abundant phase II drug metabolism 
enzyme transcript. Among the transporters, the expression value of ABCC2 transcript 
was highest. Overall, the relative abundance and expression level of the porcine drug 
metabolism genes in porcine hepatocytes are comparable to that of human primary 
hepatocytes.  
 Primary porcine hepatocytes have limited life span in culture 
To determine life span and growth kinetics of primary hepatocytes in culture, a 
MTT assay was performed on hepatocytes from three different Oncopigs mentioned 
previously. The growth and viability of the hepatocytes was assessed on days 1, 3, 
5, 8, and 15 of culture. Primary hepatocyte from all three above mentioned animals 
continued to divide up to 5 days after isolation, after which growth receded in both 
collagen coated and uncoated culture conditions (Figure 5.2A).  
We also examined the effect of culture length on hepatocyte apoptosis. The 
number of apoptotic cells increased with time in culture (Figure 5.2 B-F). Primary 
hepatocytes on culture day 1 consisted of 6.45 % apoptotic cells, increasing to 18.45, 
22.60 and 44.23 % at culture day 5, 8, and 15, respectively (Figure 5.2G). Based on 
the MTT assay and apoptosis analysis, it is clear that primary hepatocytes have a 
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limited life span in culture, with more than 50% of cells undergoing apoptosis by day 
15 of culture. Human primary hepatocytes also have a limited survival time in culture; 
survives 2-3 weeks when maintained in standard culture conditions[2,5].  
Reduced expression of hepatocyte specific and DME transcripts in primary 
hepatocytes over time in culture 
To study whether primary hepatocytes maintain hepatocyte specific functions in 
culture, we studied the expression of ALB, G6PC and sixteen other genes involved 
in drug metabolism and regulation in the three primary hepatocytes (pPH1, pPH2, 
pPH3) at different days of culture (Table 5.4 and Figure 5.4). In each of the three 
lines, most of the genes were downregulated from culture day 5, with 3-13 fold 
reductions in expression observed on culture day 15 (Table 5.4). Overall, transcript 
levels of CYPs, phase II DMEs, and transporters were not maintained in culture. 
Similar findings were reported in human primary hepatocytes [26]. 
Hepatocyte cell lines (pHCC) are highly proliferative and have unlimited life 
span in culture 
To overcome the limitations of primary hepatocytes, we activated the Oncopig 
primary hepatocytes by Ad-Cre. The three Oncopig primary hepatocyte cell lines 
were transformed into pHCC lines through exposure to AdCre. Hepatocyte specific 
functional gene expression was observed in the pHCC cell lines following activation, 
in addition to oncogenic KRASG12D and pTP53R167H expression (Figure 5.3). The cells 
were elongated, and were characterized by a clear cytoplasm and active cell divisions 
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(Figure 5.1D). The pHCC cells have been maintained in culture for 63 passages and 
have a recovery rate of more than 90% in cryopreservation. 
To further validate that the pHCC cells are transformed and have unlimited life span, 
we studied the sensitivity of the pHCC cells to doxorubicin in vitro, observing a higher 
sensitivity of the pHCC cells to doxorubicin than the primary hepatocytes (Figure 5.5). 
Doxorubicin treatment reduced the number of viable pHCC cells to less than 50% at 
concentrations from 0.5 μg/mL whereas 4 μg/mL doxorubicin was required for the 
same effect in the primary hepatocytes.   
pHCC cells expressed most important drug metabolism and regulator genes at 
levels significantly lower than primary hepatocytes 
We studied the expression of hepatocyte specific functional genes and most 
important genes involved in drug metabolism, transport and regulation in all the three 
pHCC cell lines in two passes (pass 8 and pass 15) by qPCR. All the three pHCC cell 
lines expressed all the major drug metabolism and regulation genes tested (Figure 
5.6). However, a significant downregulation of most of the CYP genes was observed 
in all the three pHCC cells compared to primary hepatocytes, in addition to reduction 
in the expression of ALB and G6PC (Figure 5.7). Most of the CYPs involved in phase 
I drug metabolism were downregulated in the range of 4 to 25 fold. The genes 
involved in phase II drug metabolism showed varying differences in expression 
(Figure 5.8); SULT1B1, SULT2A1 and GSTO1 were unchanged whereas SULT1A3 
was upregulated. Transporter ABCB1, ABCB6 and ABCC3 were upregulated. All the 
nuclear receptors involved in the regulation of drug metabolism except NR1H4 were 
downregulated from 2 to 10 fold (Figure 5.9). In brief, although pHCC cells express 
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the major drug metabolism and regulator genes tested, a marked decline in CYPs 
and nuclear receptors compared to those of primary hepatocytes was observed 
(Figure 5.10). 
pHCC cells cultured in presence of DMSO express drug metabolism and 
regulation genes comparable to primary hepatocytes 
Many researchers reported that treatment of DMSO improved the expression of 
CYPs in hepatocyte cell lines [7,26]. To improve the expression level of the drug 
metabolism and regulator genes, pHCC cells were cultured in the presence of DMSO 
in culture medium for 15 days. When cultured in William’s E medium in presence of 
2% DMSO, the all three pHCC cells showed hepatocyte like morphology, granular in 
shape (Figure 5.1E-F) and expressed hepatocyte specific functional genes like ALB, 
G6PC and HNF4A (Figure 5.3).  
Expressions of the hepatocyte specific functional genes and the most important 
genes involved in drug metabolism and regulation in all three pHCC cells (+DMSO) 
of two different passages (Pass 8 and Pass 15) were compared to day 1 cultured 
Oncopig hepatocytes (Figure 5.7-5.10). The expression of the drug metabolism and 
regulation genes in all the three independent pHCC cell lines were similar (Figure 
5.10). We studied expression of the ten most important CYPs (CYP1A1, CYP1A2, 
CYP2A19, CYP2B22, CYP2C33, CYP2C42, CYP2C49, CYP2E1, CYP3A and 
CYP7A1) and all of them except CYP1A1 and CYP7A1 had expressions comparable 
to those of primary hepatocytes (Figure 5.7). CYP1A1 had reduced expression in 
both passes and CYP7A1 had reduced expression in passage 8 of pHCC (+DMSO) 
cells than primary hepatocytes. We studied four genes involved in phase-II drug 
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metabolism (SULT1A3, SULT1B1, SULT2A1 and GSTO1) and four transporters 
(ABCB1, ABCC2, ABCB6 and ABCC3). No significant difference in SULT1B1, 
SULT2A1 and GSTO1 expression between pHCC (+DMSO) and primary 
hepatocytes was observed whereas an upregulation of SULT1A3 was found in pHCC 
(+DMSO) (Figure 5.8). The transporter ABCB1 was upregulated in pHCC (+DMSO) 
compared to cultured primary hepatocytes (Figure 5.8). The relative expressions of 
seven main nuclear receptors involved in regulation of drug metabolism (NR1I3, 
NR1I2, NR1H4, RXRA, RXRB, PPARA and PPARG) were compared between pHCC 
(+DMSO) and primary cultured hepatocytes (Figure 5.9). The expressions of all the 
nuclear receptors were not significantly different. Overall, when pHCC cells were 
cultured in presence of 2% DMSO for 15 days, the expression levels of the 
hepatocyte specific genes and most of the genes involved in drug metabolism and 
regulation were comparable to primary hepatocytes.  
Gene regulation by selective CYP modulators in pHCC cells cultured in 
presence of DMSO follows a similar pattern as in primary hepatocytes and 
human models  
To validate the effectiveness of the pHCC cells as a model of drug metabolism, 
the effect of three selective CYP modulators on all three pHCC cells cultured in the 
presence of DMSO were evaluated and compared to primary hepatocytes and 
human models.  The compounds were known inducers of CYPA1/2 (3-
methylcholanthrene), CYP3A (Rifampicin) and CYP2A6, CYP2B6, CYP3A 
(Phenobarbital) [24]. Treatment of 3-methylcholanthrene caused a significant 
upregulation of CYPA1 and CYPA2 in both primary hepatocytes and all three pHCC 
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cell lines (Figure 5.11), while the expressions of other CYPs remained unchanged. 
Upregulation of CYP2A19, CYP2B22 and CYP3A occurred following exposure to 
rifampicin. Phenobarbital exposure caused upregulation of several CYPs including 
CYP2A19 which is equivalent to human CYP2A6 [13], CYP2B22 and CYP3A (Figure 
5.11). Interestingly, the results obtained in this study are consistent with those 
available from human hepatocytes [27] and from human clinical studies [28] 
supporting the idea that this in vitro model is reliable for evaluating the potential of 
new drugs as P450 modulators.   
pHCC cells (+DMSO) recapitulate toxicity responses of primary hepatocytes 
and human models  
To validate the suitability of the pHCC cells as a drug toxicity model, the 
cytotoxicity of four hepatotoxic compounds was evaluated on three pHCC cells 
(cultured in presence of DMSO) and compared to primary hepatocytes. Toxicity of 
four reference hepatotoxic compounds, namely Aflatoxin B1 (AFB1), amiodarone, 
chlorpromazine and acetaminophen, was estimated on primary hepatocytes and 
pHCC cell lines at two different passages (pass 8 and pass 15) using standard MTT 
assay (Figure 5.12). No significant difference between pHCC cell lines and primary 
hepatocytes were observed. All four chemicals were toxic for the cell lines and as 
expected, AFB1 was the most toxic one. At 72 hr, no viable cells were observed with 
AFB1 concentrations greater than 10 µM. For the other three drugs, cell viability also 
decreased in a concentration-dependent manner. At 72 hr, the IC50s for amiodarone, 
chlorpromazine and acetaminophen were around 15 µM, 20 µM and 5 mM 
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respectively. The IC50 values of the compounds on pHCC ((+DMSO) cells were 
comparable to human hepatocytes and other in vitro human models [26]. 
Discussion  
A key challenge in drug candidate screening and development of new chemical 
entities (NCE) or new biological entities (NBE) as therapeutic agents is accurate 
determination of their toxicity and metabolism assessment [29,30]. Human primary 
hepatocytes are generally used for xenobiotic metabolism and toxicity assessment, 
however they have a lot of limitations [26,31]. Human primary hepatocytes have 
scarce and unpredictable availability, limited growth activity and undergo early 
phenotypic alterations [7]. Moreover, the expression levels of all P450s are not 
similarly maintained over time in culture. Several approaches have been reported to 
improve the preservation of liver specific functions in primary hepatocyte cultures, 
including the use of sandwich configuration by an additional layer of extracellular 
matrix [32]. However, marked phenotypic changes have been observed resulting in 
reduced expression of several CYPs [26]. An attractive alternative source of 
hepatocytes would be immortalized cells, which could make the unlimited supply of 
cells exhibiting the characteristics of differentiated hepatocytes feasible [33]. Most of 
the human hepatocyte cell lines, whether of tumoral origin or obtained by oncogenic 
transformation, lack a variable and substantial set of liver specific functions and 
consequently are unsuitable for mimicking in vivo normal parenchyma cells [5]. For 
example, the HepG2 cell line retains various hepatic functions but contain little CYP 
activity [25,34]. Immunological and physiological differences between rodents and 
humans represent major constraints for the use of rodent based models in drug 
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screening. Moreover, it is well known that induction responses in rats differ from those 
of humans due to sequence differences in the ligand domain of the nuclear receptor 
genes and CYP response element [35].  Therefore a large animal in vitro model will 
be highly beneficial for initial screening of novel drugs. In the present study we have 
developed a porcine hepatocyte cell line (pHCC) which overcomes the limitations of 
the primary hepatocytes and available human cell lines.  pHCC cells have unlimited 
life span in culture, have a recovery rate of more than 90% in cryopreservation and 
when cultured in presence of a DMSO, mimic primary hepatocytes in terms of 
expression of major drug metabolism and regulation enzymes supporting the idea 
that this in vitro model can be a better model for high throughput screening of new 
drugs as well as studies on metabolism and hepatotoxicity of chemicals.  
Cytochrome P450 enzymes responsible for drug metabolism have been 
extensively studied in pig and enzymes equivalent to human P450s have been 
identified in pig liver [12]. Porcine and human enzymes from the same P450 subfamily 
seem to have the highest sequence homology and the same substrate specificity 
[13,36]. Genetically, pigs bear key sequence homology to humans in xenobiotic 
receptors, which are divergent in mice that are responsible for modulating the 
metabolism of drugs [8]. In the present study, we have developed pHCC cell lines 
originating from transgenic Oncopigs. pHCC cells, when cultured in media containing 
2% DMSO, showed hepatocyte like morphology including granular shape and the 
expression of the hepatocyte specific genes ALB, G6PC, and HNF4A (Figure 5.3).  
  Porcine hepatocyte cell lines cultured in the presence of DMSO expresses genes 
involved in phase I and phase II drug metabolism, phase III transporters comparable 
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to those of day 1 culture of primary hepatocytes (Figure 5.7-5.10). They can be used 
as a surrogate to hepatocytes to study drug metabolism and toxicity. Ten P450s 
responsible for the metabolism of 90% of drugs were analyzed. When comparisons 
were made with primary hepatocytes, the expression level of all the studied P450s 
except CYP1A1 and CYP7A1 in pHCC (+DMSO) was comparable to primary 
hepatocytes.  In the human HEPG2 cell line, no transcripts were detected for CYPs 
2B6, 2C9, 2E1 and 3A4 [5]. Recently, HepaRG cells derived from a human liver 
hepatocellular carcinoma in presence of DMSO have been shown to express liver 
function genes and major CYPs at levels markedly lower (5-50 fold) than primary 
hepatocytes [26,37]. In contrast, porcine pHCC cells have the potential to express 
most of the CYPs at level comparable to primary hepatocytes. Expression of 
Glutathione-S-Transferase O1 in the pHCC cell lines was comparable to cultured 
hepatocytes, while SULT1A1 were upregulated. Nuclear receptors NR1I2, NR1H4, 
RXR, NR1I3 and PPARA play the most important roles in regulating most of the drug 
metabolizing enzymes and transporters [38] and have been considered the key 
xenobiotic sensors for years. These receptors, which are most highly expressed in 
the liver, were also expressed in the porcine hepatocyte cell lines in presence of 
DMSO at level comparable to primary hepatocytes (Figure 5.8).  
We studied the effect of three selective CYP modulators on hepatocyte cell lines 
and primary hepatocytes. 3-methylcholanthrene is a selective inducer of CYP1A1/2 
[24]. In contrast, phenobarbital and rifampicin increases several enzymes [24,39]. In 
the present study, 3-methylcholanthrene treatment induced significant increases in 
the expression of CYP1A2 and CYP1A1 and phenobarbital and rifampicin 
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significantly increased the expression of several CYPs in both primary hepatocytes 
and pHCC (+DMSO) cell lines (Figure 5.11). The results obtained in this study are 
consistent with those of human primary hepatocytes and from clinical studies 
[27,28,40] which support the idea that this in vitro model is reliable for evaluating the 
potential of new drug entities.  
In agreement with the active expression of phase-I and phase-II xenobiotic-
metabolizing enzymes, the suitability of the hepatocyte cell lines cells for 
determination of chemical metabolism profiles was supported by the cytotoxicity 
effects of several hepatotoxicants (Figure 5.12). Toxicity of AFB1 and acetaminophen 
is dependent on electrophilic metabolites by P450 dependent reactions [41]. AFB1 
and acetaminophen showed marked toxicity on pHCC cells, indicating that they 
express the different enzymes involved in the biotransformation at suitable levels. 
In conclusion, we have developed a hepatocyte cell lines derived from the 
transgenic Oncopig. Our results demonstrate that, in conditions in which cells attain 
a differentiated hepatocyte-like morphology, drug metabolism enzymes remain at 
levels comparable to those measured in primary hepatocytes. hepatocyte cell lines 
represent a porcine hepatocyte cell line, capable of expressing both phase-I and 
phase-II drug metabolism enzymes as well as membrane transporters normally found 
in liver. They represent a prominent alternative to primary hepatocytes. They 
overcome the limitations of primary hepatocytes and available human cell lines, can 
be easily cryopreserved and functional activity remain stable over several passages. 
They have the ability to carry out normal biotransformation reactions by metabolic 
CYP enzymes, which are required for toxicity of some chemicals, making the cell line 
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a potentially useful model for toxicological testing. In conclusions, hepatocyte cell 
lines represent a useful and predictive model for high throughput screening of new 
drugs as well as studies on metabolism and hepatotoxicity of chemicals.  
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Figures and Tables 
 
Figure 5.1. Morphology of porcine primary hepatocytes (pHC) and Hepatocyte Cell Lines 
(pHCC) 
All the three porcine primary hepatocytes (pPH) showed similar morphology; pPH1 is 
presented in the figure. Same is true for hepatocyte cell lines (pHCC)  
(A) H&E stained porcine primary hepatocytes; the cells are polygonal in shape with granular 
cytoplasm. (B) Expression of cytokeratin in primary hepatocytes. (C) Vimentin staining of the 
primary hepatocytes; primary hepatocytes were negative for vimentin. (D) H&E stained 
pHCC cells cultured in absence of DMSO (20X). The cells are elongated, characterized by a 
clear cytoplasm and actively dividing cells. (E) H&E stained pHCC cells cultured in presence 
of 2% DMSO (10X) (F) H&E stained pHCC cells cultured in presence of 2% DMSO (40X). 
The cells are granular in shape and show hepatocyte like morphology.   
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Figure 5.2. Porcine primary hepatocytes have limited life-span in culture 
 (A) Hepatocyte growth at different days of culture. A MTT assay was done to determine the 
proliferation of primary hepatocytes in culture. A cell proliferation curve was prepared by 
plotting the optical density of the hepatocytes against respective days of culture. The values 
and error bar represent average and standard deviations of three independent set of 
experiments. Student T test was performed to find out significant differences between two 
culture conditions. Apoptosis analysis of primary hepatocytes after (B) 1, (C) 3, (D) 5, (E) 8, 
and (F) 15 days in culture. Apoptotic cells were stained by Annexin-V and detected by flow 
cytometry. The apoptotic cell death was quantified as Annexin V+ (both PI-negative and 
AnnexinV-positive) cells. The percentage of apoptotic cells increased over time and after 15 
days in culture more than 50% of primary hepatocytes was either apoptotic or dead. (G) The 
histogram shows the mean number of apoptotic hepatocytes (mean ± SD) from three 
experiments. One-way analysis of variance (ANOVA) followed by Dunnett post-test was 
performed to determine significant difference among treatments. * denotes p≤0.05; ** 
denotes p≤0.01; *** denotes p≤0.001; **** denotes p≤0.0001 
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Figure 5.3. Primary hepatocytes and pHCC cells express hepatocyte specific genes 
Agarose Gel electrophoresis of RT-PCR products of hepatocyte-specific marker genes; 
porcine albumin (ALB); HNF4 alpha (HNF4A) and Glucose-6-phosphatase (G6PC). pHCC 
cells expressed the transgenes (KRASG12D and TP53R167H) while primary hepatocytes did not. 
Oncopig fibroblasts were used as a negative control. pPH denotes porcine primary 
hepatocytes and pHCC denotes porcine hepatocyte cell line 
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Figure 5.4. Expression profiles of drug metabolism genes in different days of culture of 
primary porcine hepatocytes. Heatmap of the normalized expression level of genes 
commonly involved in drug metabolism. Expression is represented as z-scores.  
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Figure 5.5. pHCC cells are more sensitive to doxorubicin 
All the three pHCC cell lines showed more sensitivity towards doxorubicin; the figure 
represents average values. Doxorubicin sensitivity assay shows pHCC cells are more 
sensitive to doxorubicin toxicity than primary hepatocytes. Doxorubicin treatment reduced 
the number of viable pHCC cells to less than 50% at concentrations from 0.5 μg/ml. 4 μg/ml 
doxorubicin was required for the same effect in the primary hepatocytes. pPH denotes 
porcine primary hepatocytes and pHCC denotes porcine hepatocyte cell line 
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Figure 5.6. Porcine primary hepatocytes (pPH) and hepatocyte cell lines (pHCC) express 
drug metabolism and regulation genes. Reverse transcriptase (RT) PCR was done to detect 
the expression of the genes. N. control denotes negative control. 
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Figure 5.7. Differential expression profiles of hepatocyte specific and phase I DME (CYP) 
transcripts in primary hepatocytes and pHCC cell lines.  
All the three cell lines (pHCC) showed similar expression patterns and the figure represents 
average values. Real time RT-PCR was performed to analyze the expression of the two 
hepatocyte specific genes (A) and ten phase I DME genes (B). The values and error bars 
represent average and standard deviations of three independent set of experiments. One-
way analysis of variance (ANOVA) followed by Dunnett post-test was performed to find out 
significant difference among control and treatments. * denotes p≤0.05; ** denotes p≤0.01; 
*** denotes p≤0.001; **** denotes p≤0.0001. pPH denotes porcine primary hepatocytes and 
pHCC denotes porcine hepatocyte cell line. 
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Figure 5.8. Differential expression profiles of phase II and phase III transcripts in primary 
hepatocytes and pHCC cell lines.  
All the three cell lines (pHCC) showed similar expression patterns and the figure represents 
average values. Real time RT-PCR was performed to analyze the expression of the four 
phase II DME genes (A) and four phase III transporters (B). The values and error bars 
represent average and standard deviations of three independent set of experiments. One-
way analysis of variance (ANOVA) followed by Dunnett post-test was performed to find out 
significant difference among control and treatments. * denotes p≤0.05; ** denotes p≤0.01; 
*** denotes p≤0.001; **** denotes p≤0.0001. pPH denotes porcine primary hepatocytes and 
pHCC denotes porcine hepatocyte cell line. 
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Figure 5.9. Differential expression profiles of nuclear receptor transcripts in primary 
hepatocytes and pHCC cell lines. 
All the three cell lines (pHCC) showed similar expression patterns and the figure represents 
average values. Real time RT-PCR was performed to analyze the expression of the seven 
nuclear receptors involved in regulation of drug metabolism. The values and error bars 
represent average and standard deviations of three independent set of experiments. One-
way analysis of variance (ANOVA) followed by Dunnett post-test was performed to find out 
significant difference among control and treatments. * denotes p≤0.05; ** denotes p≤0.01; 
*** denotes p≤0.001; **** denotes p≤0.0001. pPH denotes porcine primary hepatocytes and 
pHCC denotes porcine hepatocyte cell line. 
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Figure 5.10. Expression profiles of drug metabolism and transport genes in pPH and pHCC 
cell lines. Heatmap of the normalized expression level of genes commonly involved in drug 
metabolism and regulation, grouped by their functional categories. Expression is represented 
as z-scores. 
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Figure 5.11. Effect of selective CYP modulators on P450 enzyme transcript expression in 
primary hepatocytes and pHCC (+DMSO) cell lines. (Porcine hepatocytes and pHCC cell 
lines (8th passage) were exposed to 2 µm 3-methylcholanthrene, 1 mM phenobarbital, or 50 
µM rifampicin for 24 hours. The expression levels of major drug-metabolizing porcine P450 
enzymes were quantified by quantitative RT-PCR.The values and error bars represent 
average and standard deviations of three independent set of experiments. One-way analysis 
of variance (ANOVA) followed by Dunnett post-test was performed to find out significant 
difference among control and treatments. * denotes p≤0.05; ** denotes p≤0.01; *** denotes 
p≤0.001; **** denotes p≤0.0001. pPH denotes porcine primary hepatocytes and pHCC 
denotes porcine hepatocyte cell line. 
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Figure 5.12. Cytotoxic effects of Aflatoxin B1, amiodarone, chlorpromazine, and 
acetaminophen on pHCC (+DMSO) cell lines. All three pHCC (+DMSO) cells from two 
different passages (8th and 15th) were exposed to chemicals for 72 h. Cell viability was 
assessed using standard a MTT test. The results were normalized to untreated cells. All three 
cell lines recorded similar toxicity response and expressed as means ±S.D. (n=3 cultures) 
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Table 5.1  
Genes  
Primers 
Sequences (5’-3’) 
Ta 
(°C) 
CYP1A1 
 
Forward ATGAGTTCGGGGAGGTGACT 57 
Reverse TCCGACAGCTGGATATTGGC 
CYP1A2 
 
Forward AGGAGAATTCCAGCACCAGC 57 
Reverse TCGGAAGAGCTCCAGGATGA 
CYP2A19 
 
Forward AAGAAACCGGATGTGGAGGC 58 
Reverse GAGCCCAGCATAGGGAACAC 
CYP2B22 
 
Forward TTCGCCTACAGAGATCCCGA 61 
Reverse CCGGCAAAGAAGAGCGAAAG 
CYP2C33 
 
Forward CCCTGCGTCTCTTTCCAAGT 61 
Reverse CCTCAGGGTCATGAGGGAGA  
CYP2C42 
 
Forward GGTTGTGGTCCTGGTGCTTA 60 
Reverse ATTCCGCAAGGTCATGAGGG 
CYP2C49 
 
Forward CCCAACCCAGAGGTGTTTGA 56 
Reverse CAAAGCCCAGAAGAGGACGA 
CYP2E1 
 
Forward GCACAAGGACAAAGGGGTCA 58 
Reverse CTTCCAGGCAGGTAGCGTAG 
CYP3A29 
 
Forward GACCGTAAGTGGAGCCTGAC 60 
Reverse CTGATCAGCACCCCGGAAAA 
CYP3A22 
 
Forward GAGAGGCAAAGAGCAGCACA  
Reverse TTCCGCCGATTTGTGAAAGC 
CYP3A39 
 
Forward CGTGATGATGGTACCGGTTTTC 61 
Reverse TGAGGAACCAAGCCCAAGTC 
CYP3A46 
 
Forward AGCTCCCAGGGACTTATCCA 61 
Reverse TCTGCATGTCTGACCCTCAT 
CYP7A1 
 
Forward GCCTGTGCTAGACAGTATCATCA 62 
Reverse GACAGATCGTAGCCCCTGAC 
GSTO1 
 
Forward GCCTTTGCCTCCTATGCAAC 57 
Reverse TCAAGGTCATTCAGGTGGGC 
SULT1A3 
 
Forward TGCAGTGACCACACCATACC 57 
Reverse GACACTTCTGCAGGTCACCA 
ABCB1 
 
Forward GGCCACATGGACTTTCAGGA 60 
Reverse ATGTCTGGTCGAGTGGGGTA 
ABCC2 
 
Forward GCTTGGACCAGTGACTCTAAA  
Reverse CCCAGGAAGCACATAAGCCA 
ABCG2 
 
Forward CCTGAGATTGGAGCCCTTGG 61 
Reverse GGGTCCCAGAATGGCATTGA 
Table 5.1. Primer sequences for reverse transcription PCR 
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Table 5. 2  
Gene Name Primers Sequences (5’-3’)  
GAPDH 
 
Forward GGCAAATTCCACGGCACAGTCA 
Reverse CTGGCTCCTGGAAGATGGTGAT 
 ACTB 
 
Forward GCAAATGCTTCTAGGCGGACTGT 
Reverse CCAAATAAAGCCATGCCAATCTCA 
Porcine 
Albumin 
Forward TGGTGACTTGGCTGACTGCTG 
Reverse TGTCGGGGTTATCATTTTTGTGTTG 
HNF4A 
 
Forward AGTCCCAGAGTGGTAGTGGAAAG 
Reverse CAGATGGTGAAGGGTGGCATTG 
G6PC 
 
Forward ATTGAAAGACGATGACTGTGCCAA 
Reverse CAAAGGAGGAAGGAGTTCTGAGC 
CYP1A1 
 
Forward AAGAGGCAGAGGTGAAGTGGTGAA 
Reverse GAGAAGAAGGAAGGCAGTGAAGTGATAG 
CYP1A2 
 
Forward ACACCTTCTCCATTGCCTCAGACC 
Reverse GCACTCAGCCTCCTTGCTCAC 
CYP2A19 
 
Forward CCGAAGAGTCACCAAGGATACCAAG 
Reverse ACAGAGCCCAGCATAGGGAACA 
CYP2B22 
 
Forward CAGATGAGTAAACAGAGCCCGAGAA 
Reverse CGAGAGCCAAGGAGACAGCA 
CYP2C33 
 
Forward TGGAAGAAAAATCACAAGAGGAGAAGG 
Reverse TTGGAAAGAGACGCAGGGATGT 
CYP2C42 
 
Forward TACAGAGACAACAAGCACCACCA 
Reverse CTGCCAATCACACGGTCAATC 
CYP2C49 
 
Forward CTTGTGGAGGAGTTGAGAAAAACC 
Reverse TTGTGGAAAATGATGGAGCAGA 
CYP2E1 
 
Forward ACACCCTGCTGATGGAAATGGA 
Reverse GTGGTCTCTGTCCCCGCAAA 
CYP3A 
 
Forward TACCTGCCCTTTGGGACTGGAC 
Reverse AGTTCTGCAGGACTCTGACGA 
CYP7A1 
 
Forward TTCTGCTACCGAGTGATGTTTGAGG 
Reverse AGGTTGTTTAGGATGAGTGCTTTCTGTG 
SULT1A3 
 
Forward GACCACAGCATCTCAGCCTTCAT 
Reverse CTGCCATCTTCTCAGCATAGTCG 
SULT2A1 
 
Forward AAATGCTGCAAGAGGTGAGGGAGG 
Reverse ATCCCCCTTGGAGAGAATCAGGCA 
SULT1E1 
 
Forward GAGAAAGGGGATTGCAGGAGACTG 
Reverse GTAGACCCCTTCATTTGCTGCTCA 
GSTO1 
 
Forward GAGATTCTGTCCTTTCGCCCAGAG 
Reverse GATGACTTGATGCCGGATTCCCTT 
GSTK1 
 
Forward GGTACACCATCCACCGTTAGTCTC 
Reverse CACACAAACACCAGCAAAGACACA 
ABCB1 
 
Forward TGGCAGTGGGACAGGTTAGTTC 
Reverse CACGGTGCTTGAGCTGTCAATC 
ABCB6 
 
Forward TGTTGTCCCAAGGTGGTGTGTATG 
Reverse GCTGAAATGGATTTCCCTCCAGGT 
ABCC2 
 
Forward GTGGCTGTTGAGCGAATAAATGAATAC 
Reverse TGCTGGGCCAACCGTCTG 
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Table 5.2 (cont.) 
Gene Name Primers Sequences (5’-3’)  
ABCC3 
 
Forward TGATGCAGACGCTGATCTTACACC 
Reverse ACTCACGTTTGACGGAATTGGTGA 
ABCG2 
 
Forward GATCTTTTCGGGGCTGTTCCTCA 
Reverse TGAGTCCCGGGCAGAAGTTTTGT 
PXR 
 
Forward GACAACAGTGGGAAAGAGAT 
Reverse CCCTGAAGTAGGAGATGACT 
FXR 
 
Forward CATTCAACCATCACCACGCAGAGA 
Reverse GCACATCCCAGACTTCACAGAGA 
CAR 
 
Forward GAAAGCAGGGTTACAGTGGGAGTA 
Reverse CTTCAGGTGTTGGGATGGTGGTC 
LXRA 
 
Forward TCCAGGTAGAGAGGCTGCAACATA 
Reverse AGTTTCATTAGCATCCGTGGGAAC 
LXRB 
 
Forward GAGTCTTCCTGAGAGGGGCAGATA 
Reverse CGTGGTAGGCTTGAGGTGTAAGC 
PPARA 
 
Forward AATAACCCGCCTTTCGTCATACAC 
Reverse GACCTCCGCCTCCTTGTTCT 
PPARG 
 
Forward CCATGCTGTCATGGGTGAAACTCT 
Reverse GTCAACCATGGTCACCTCTTGTGA 
RXRA 
 
Forward CCTTCTCGCACCGCTCCATA 
Reverse CGTCAGCACCCTGTCAAAGATG 
RXRG 
 
Forward CTTCCCGTTCCCCAAACGTGAT 
Reverse CTTCCAGAAAAGATCCCCAGTCCC 
 
Table 5.2. Primer sequences for real-time PCR 
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Table 5.3 
 
Table 5.3: Relative abundance of drug-metabolizing genes in porcine and human primary 
hepatocytes 
Expression value is a relative number calculated based on the assumption that average 
expression level of two housekeeping genes GAPDH and ACTB is 1.  
Expression values of human primary hepatocytes are reported by Guo et al., 2011 
pPH1: Porcine primary hepatocyte 1, pPH2: Porcine primary hepatocyte 2, pPH3: Porcine 
primary hepatocyte 3, hPH: Human primary hepatocyte 
# Porcine CYP2A19 is equivalent to human CYP2A13 
$ Porcine CYP2C33 is equivalent to human CYP2C9 
£ Porcine CYP2C49 is equivalent to human CYP2C18 
 
 
 
 
 
Gene pPH1 pPH2 pPH3 hPH 
Phase I DME 
CYP1A1 0.00273 0.00288 0.00312 0.0028 
CYP1A2 0.02187 0.02305 0.02493 0.0173 
CYP2A19# 0.00038 0.00043 0.00045 0.0002 
CYP2C33$ 0.05513 0.07583 0.07053 0.0512 
CYP2C49£ 0.07076 0.08120 0.07839 0.0754 
CYP2E1 0.01484 0.01153 0.01247 0.0174 
CYP3A 0.05668 0.05942 0.04987 0.0115-
0.0562 
CYP7A1 0.00034 0.00036 0.00039 0.0001 
Phase II DME 
SULT1A3 0.01827 0.02032 0.02025 0.0214 
SULT1B1 0.03654 0.04064 0.04051 0.0403 
SULT2A1 0.03457 0.03791 0.03526 0.0442 
SULT1E1 0.00108 0.00118 0.00110 0.0015 
GSTO1 0.29733 0.29502 0.29075 0.2539 
GSTK1 0.14151 0.12309 0.15677 0.1393 
Phase III DME 
ABCB1 0.15931 0.17591 0.16307 0.2388 
ABCB6 0.08133 0.14289 0.08153 0.1141 
ABCC2 0.38237 0.04976 0.43937 0.4696 
ABCC3 0.19119 0.20419 0.19184 0.2403 
ABCG2 0.00216 0.00237 0.002204 0.0061 
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Table 5.4 
Gene Fold change in different days in culture compared to day ‘0’ 
Day 3 Day 5 Day 8 Day 15 
ALB -1.35 -1.95 -6.30 -10.62 
G6PC -1.21 -1.84 -4.18 -8.15 
CYP1A1 -1.08 -1.18 -1.74 -3.95 
CYP1A2 -1.01 -1.23 -2.34 -3.95 
CYP2A19 -1.12 -2.01 -2.12 -4.20 
CYP2B22 -1.16 -1.80 -6.18 -8.46 
CYP2C33 -1.19 -2.61 -4.49 -8.20 
CYP2C49 -1.14 -1.48 -4.67 -13.06 
CYP2E1 -1.09 -1.35 -2.88 -4.65 
CYP3A -1.14 -2.15 -3.50 -5.30 
GSTO1 -1.11 -1.56 -3.42 -4.40 
SULT1A3 -1.35 -2.23 -4.71 -5.36 
ABCB1 -1.09 -1.20 -1.81 -3.90 
ABCC2 -1.14 -1.33 -2.37 -8.35 
 
Table 5.4. Fold change of the hepatocyte specific genes and DMEs in primary hepatocytes 
in different days of culture. 
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